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Virus-specific memory CD8+ T cells play a prominent role in protection of a host from recurring 
and persistent virus infection.  It is known that memory CD8+ T cells undergo a series of 
differentiation stages to become fully matured effector cells. There are several important aspects 
of the current CD8+T cell memory phenotype model that need to be more thoroughly defined.  
 In specific aim 1, it was hypothesized that CD27+CD28+ undifferentiated CD8+ memory 
T cells specific for non-persistent virus influenza A (FluA) would have phenotypic markers 
associated with more differentiated (effector) phenotypes.  Results showed that in spite of the 
phenotypic enrichment of FluA-specific memory CD8+ T cells in the undifferentiated stage, they 
displayed effector markers indicative of late stage differentiated effector cells.   
 In specific aim 2, it was further hypothesized that the most undifferentiated CD62L+ 
central memory CD8+T cells would have the effector function including immediate cytoplasmic 
production of IFN-γ upon antigenic-stimulation..  Results  showed that CD62L+ CD8+ T cells are 
capable of immediate IFN-γ production after antigen-specific stimulation in the presence of the 
CD62 sheddase inhibitor, GM6001, highlighting the need to re-evaluate the defining markers of 
virus-specific central memory CD8+ cells and/or their functions.   
 In specific aim 3, this dissertation tests the hypothesis that memory-effector 
differentiation of HIV-1-specific memory CD8+ T cells is impaired during the course of 
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persistent HIV-1 infection.  Detailed comparison of CD27 and CD57 co-expression on HIV-1-
specific CD8+ T cells showed that these cells had a significantly lower proportion of the CD27–
CD57high effector subset.  Moreover, these cells did not display progression from CD27+CD57– 
(immature memory), through CD27lowCD57low (transitional memory-effector) to CD27–CD57high 
(effector subset) that was seen in well differentiated EBV-specific CD8+ T cells and was 
common in CMV-specific CD8+ T cells.  These observations suggest that the normal course of 
HIV-1-specific CD8+ T cell memory-effector differentiation is impaired during the course of 
persistent HIV-1 infection.  
 Elucidation of memory-effector differentiation of virus-specific CD8+ T cells has 
significant public health implications.  Understanding the impairment of memory-effector 
differentiation of HIV-1-specific CD8+ T cells, for instance, will greatly facilitate a design of 
effective vaccine against progressive HIV-1 infection.   
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I. 
 INTRODUCTION 
 
A. Virus-Specific CD8+ T Cell Memory-Effector Differentiation 
1. MHC Class I Tetrameric Reagent 
CD8+ T cells play a major role in the cell mediated immunity against various types of pathogens.  
One of the most critical features that differentiates CD8+ T cells from other immune cells is their 
antigen-specificity.  Characterization of CD8+ T cells specific for a particular antigen is 
therefore, essential for understanding the biology of CD8+ T cells, and there has been great 
interest in accurately quantitating antigen-specific CD8+ T cells.   
 Historically, the frequency of antigen-specific CD8+ T cells was quantitated by direct 
cloning and limiting dilution assay (LDA).  There are several caveats, however, of using the 
LDA for estimation of the frequency of antigen-specific CD8+ T cells.  The most significant 
caveat is a requirement of in vitro manipulation involving expansion of antigen-specific CD8+ T 
cells over many weeks.  The frequency of antigen-specific CD8+ T cells derived from the LDA is 
markedly affected by the proliferative potential of antigen-specific CD8+ T cells.  In fact, the 
LDA greatly underestimates the ex vivo frequency of antigen-specific CD8 T cells, particularly if 
the antigen-specific CD8+ T cells contain a large proportion of cells with less than adequate 
proliferative potential.   
 A replacement for LDA that could accurately quantitate antigen-specific CD8+ T cells ex 
vivo appeared in 1996.  Altman et. al. (2) reported on the new revolutionary methodology using 
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an MHC class I tetrameric reagent that allowed visualization and quantitation of the antigen-
specific CD8+ T cells ex vivo by flow cytometry.  As its name suggests, the MHC Class I 
tetrameric reagent consists of four recombinant MHC class I monomers, each loaded with a 
peptide derived from an epitope of a particular antigen.  Two components of the recombinant 
MHC class I monomer (heavy chain and β2M) are produced in bacteria.  After purification, they 
are allowed to recombine and form the mature MHC class I monomer.  The recombinant MHC 
class I monomer has a biotinylation tag where biotin is covalently added by a biotinylation 
transferase (Figure 1).  A tetrameric complex formed in the presence of streptavidin labeled with 
a fluorescent dye, allows detection of the antigen-specific CD8+ T cells by the flow cytometer.   
 Another benefit of using the MHC class I tetrameric reagent is to conduct phenotypic and 
functional assessments of antigen-specific CD8+ T cells.  With advances in the modern flow 
cytometry, this reagent makes it possible to address many functional and phenotypic aspects of 
antigen-specific CD8+ T cells.  The phenotypic assessment of many antigen-specific CD8+ T 
cells has helped establish a model of antigen-specific CD8+ T cell development and 
differentiation.  Also, combined with functional assays,  it is possible to measure capacities of 
antigen-specific CD8+ T cells for apoptosis, proliferation and effector functions both in vitro and 
in vivo (3, 4).   
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Figure 1. A theoretical structure of a MHC Class I tetrameric complex. (A) Four recombinant 
MHC Class I monomers (dark blue) are oligomerized with streptavidin (light blue) conjugated 
with phycoerythrin (red) Adapted from McMicheal et. al. (5) (a copyright permission granted 
from Nature Publishing Group (http://www.nature.com).  (B) Schematic drawings of a wild type 
(left) and a recombinant (right) MHC class I monomers. A heavy chain (light blue) contains 
three globular domains associated non-covalently with β2M (green and purple) and a peptide 
(black triangle).  While the wild type monomer has transmembrane (blue and green) and 
cytoplasmic (red) domains, the recombinant monomer has a biotinylation sequence (BSP) where 
biotin is attached covalently.  
 
 Significantly, the recent development of MHC class II tetrameric reagents in addition to 
the MHC class I tetrameric reagent will offer nearly complete phenotypic and functional 
assessments of T cell immunity to various pathogens and tumors.   
 
2. Differentiation Associated Phenotypic Markers 
Prior to the development of the MHC class I tetrameric reagent, memory-effector differentiation 
of virus-specific CD8+ T cells was modeled by phenotypic and functional assessment of bulk 
CD8+ T cells.  These early studies found several surface molecules that could be used as reliable 
phenotypic markers for distinguishing functional subsets such as naïve, memory and effector 
BSP 
β2M 
α1 α2 
α3 
Biotin 
β2M 
α1 α2 
α3 
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subsets.  More recent studies using MHC class I tetrameric reagents have added many more 
surface molecules to a growing list of differentiation-associated phenotypic markers.  
Importantly, the most frequently used phenotypic markers typically have clear cellular functions.  
CD62L (L-selectin) mediates adhesion of lymphocytes to high endothelial venules of secondary 
lymphoid tissues (6), and augments recruitment of activated effector CD8+ T cells to 
inflammatory sites (7).  CCR7 is a chemokine receptor for a class of CC chemokines, ELC 
(CCL19) and SLC (CCL21), and a critical molecule for T lymphocyte homing to secondary 
lymphoid organs (8).  CD27 belongs to the TNFR superfamily.  Its primary cellular function is to 
induce memory and effector differentiation through interaction with CD70 (9).  CD28 belongs to 
an immunoglobulin superfamily, and its main function is to provide T cell co-stimulation to 
promote proliferation, survival, and effector differentiation (10).  CD57, also known as HNK-1 
antigen, is a modified carbohydrate (glucuronic acid 3-sulfate) (11).  Its primary cellular function 
is to mediate cell-cell interaction, and is also a co-receptor for IL-6 (12).  CD45R isoforms have 
a common cytoplasmic phosphatase domain, and appear to regulate T cell receptor (TCR) 
signals.  Isoform switch occurs by alternative splicing, which generates the longer RA and 
shorter RO products.  An exact triggering mechanism of isoform switch is not clearly understood 
(13).   
 Phenotypic subsets are usually defined by combination of at least two phenotypic 
markers.  Modern flow cytometers allow simultaneous detection of 4 parameters (4 distinct 
surface markers).  Usually, two parameters (a virus-specific MHC Class I tetrameric reagent and 
CD8) are reserved for defining virus-specific CD8+ T cells, and the remaining two parameters 
are used to delineate phenotypic subsets.  Notably, the most advanced cytometer has 11 
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parameters available for simultaneous determination of phenotypic marker expression on a single 
cell (14), permitting a more sophisticated phenotypic analysis.   
 
3. Memory-Effector Differentiation Models 
Early studies characterizing memory-effector CD8+ T cell differentiation showed that antigen-
specific CD8+ cytotoxic T lymphocyte (CTL) precursors were enriched in a CD45RA–CD45RO+ 
subset (15).  Later studies found that the CD45RA+ subset contained CD8+ T cells with low 
CD62L (16), low CD27 (17), and high CD11c/18 expression (18), which were phenotypic 
characteristics of effector cells.  Following these studies, Hamann et al. (19) proposed a model of 
memory-effector CD8+ T cell differentiation based on CD27 and CD45RA expression.  By direct 
examination of functional properties (cytokine production and cytotoxic potential) of an enriched 
CD27+/–CD45RA+/– subset, they were able to show that naïve (CD27+CD45RA+), memory 
(CD27+CD45RA–) and effector (CD27–CDRA+) subsets of CD8+ T cells could be distinguished 
phenotypically.   
 More recent studies have added greater complexity to the model by incorporating 
migratory properties of T cells.  These studies also provided evidence that the memory subset is 
highly heterogeneous phenotypically and functionally.  The migratory property of CD8+ (and 
CD4+) T cells is determined by a pattern of chemokine receptor expression.  The most relevant 
chemokine receptor to CD8+ T cell memory-effector differentiation is CCR7.  It was shown that 
the memory CD8+ T cells could be further divided into two subsets based on expression of CCR7 
and CD45RA (20).  CCR7+CD45RA–(CD62L+) CD8+ T cell, a central memory cell (TCM), have 
the homing capacity to lymphoid organs, and lack cytoplasmic effector molecules (e.g. perforin 
and granzymes) and immediate effector function (e.g. cytoplasmic IFN-γ production).  In 
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contrast, CCR7–CD45RA– (CD62Llow) CD8+ T cells are effector memory (TEM) cells that have 
homing capacity to non-lymphoid organs, and possess immediate effector functions.  Based on 
these observations, Sallusto et. al. (20) proposed 4 stages of CD8+ T cell differentiation: 
CCR7+CD45RA+ (naïve), CCR7+CD45RA– (TCM), CCR7–CD45RA– (TEM), and CCR7–
CD45RA+ (effector).  Furthermore, TCM appears to have two new subsets, CCR4+ type 2 
polarized, and CCR4– conventional type 1 polarized TCM (21).   
 These studies have built a foundation of the memory-effector CD8+differentiation model.  
Indeed, when the MHC class I tetrameric reagent became widely available, a similar 
combination of phenotypic markers was used to characterize virus-specific CD8+ T cells.  Recent 
studies have shown that virus-specific CD8+ T cells undergo similar phenotypic stages of 
memory-effector differentiation defined by these earlier studies, though the earlier models of 
memory-effector CD8+ T cell differentiation have been greatly refined in recent years.  
 By utilizing a large number of MHC class I tetrameric reagents, Appay et. al. (22) 
determined and compared phenotypes of CD8+ T cells specific for human persistent virus during 
acute  and chronic infection.   They found that such CD8+ T cells regardless of virus-specificity 
expressed predominantly activated (CD38+HLA-DR+Ki-67+), immature/undifferentiated 
(CD27+CD28+) phenotype, and cytotoxic effector molecules (perforin and granzymes).  During 
chronic infection, however, these virus-specific CD8+ T cells were enriched in the particular 
stage of memory-effector differentiation according to their specific virus.  This implies that 
classical models of CD8+ T cell differentiation may not accurately ascribe differentiation of 
virus-specific CD8+ T cells.  Based on these results, four stages of virus-specific CD8+ T cell 
differentiation have been proposed based on expression of CD27 and CD28 (22, 23).  The model 
shows virus-specific CD8+ T cell memory-effector differentiation progressing from 
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CD27+CD28+ (early memory) through CD27+CD28– (intermediate memory) to CD27–CD28– 
(late memory effector). 
 Another equally important model (24) of virus-specific CD8+ T cell memory-effector 
differentiation was proposed based on the earlier work of Hamman et. al. (19) and the 
phenotypic and functional characterization of CMV-specific CD8+ T cells (25).  Unlike the 
previous linear model, these authors proposed a branched model of virus-specific CD8+ T cell 
memory-effector differentiation.  Virus-specific CD8+ T cells progress from 
CD27+CD28+CD45RA+ (naïve precursor), through CD27+CD28+CD45RA– (acute effector stage) 
and CD27+CD28+/–CD45RA– (recovery stage), to either CD27–CD28–CD45RA+ (effector 1) or 
CD27+CD28–CD45RA+ (effector 2).  
 It is worth noting mouse models of CD8+ T cell memory-effector differentiation because 
there are several important aspects that human models cannot provide.  One of such important 
aspect is that the dynamics of CD8+ T cell differentiation is fully known in the mouse model 
(26).  During primary infection, naïve precursors of virus-specific CD8+ T cells expand and 
become effectors; soon after primary infection (during a contraction/death period), a majority of 
these effectors undergo apoptotic death.  A fraction of the virus-specific CD8+ T cell survives 
during a contraction period forms the immunological memory.   
 Although a similar process occurs in the human (24), there are important differences 
between human and mouse virus-specific memory-effector CD8+ T cells with respect to their 
phenotypic and functional characteristics.  The most significant difference is that unlike virus-
specific CD8+ T cells in humans, the phenotype of virus-specific mouse CD8+ T cells during the 
acute phase of infection is the effector type (CCR7lowCD27lowCD28low), and a majority of these 
cells differentiate to TEM, and then become TCM in a later phase of acute infection (1) (Figure 2).  
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In the mouse, TCM cells are thought to be a source of long-term memory.  Conceptually, this 
makes sense, since TCM cells have a greater proliferative capacity and lack immediate effector 
functions, and their phenotype resembles naïve and immature memory subsets (27).  Recently, 
mouse TCM cells have been shown to be equally or more effective in protecting the host from 
systemic or peripheral viral challenge than TEM cells (28).  Also, in humans, a significantly 
higher proportion of TCM cells have recently been shown to have immediate effector functions 
(29), challenging the previously proposed function of TCM (20).  However, unlike mouse TCM, 
the actual protective immunity of TCM in human has not been assessed in vivo.   
 
 
Figure 2.  A mouse model of memory-effector virus-specific CD8+ T cells proposed by Wherry 
et. al. (1) (a copyright permission granted from Journal Department, American Society of 
Microbiology).   
 
 There are similarities between human and mouse models of virus-specific CD8+ T cell 
memory-effector differentiation.  The most important similarity is significance of CD4+ T cells 
in modulating CD8+ T cell memory-effector differentiation through so-called “CD4 help.”  In the 
mouse, the absence of “CD4 help” results in complete functional impairment of lymphocytic 
choriomeningitis virus (LCMV)-specific CD8+ T cells, resulting in failure to control persistent 
LCMV infection (30).  During primary infection, primed virus-specific CD8+ T cell in the 
absence of “CD4 help” have substantially reduced potential to expand after secondary 
stimulation (31).  Similarly, in humans, the absence of “CD4 help” due to progressive HIV-1 
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infection results in the impairment of EBV- and HIV-1-specific CD8+ T cell differentiation (32).   
Also, survival of adoptively transferred HIV-1-specific CD8+ T cells correlates with the presence 
of CD4+ T cells (33).  These observations imply that the function of CD4+ T cells is 
evolutionarily conserved, and critically involved in the regulation of CD8+ T cell memory-
effector differentiation.  
 
B. The CD8+ T Cell Response to Persistent Virus Infection 
There are several families of viruses that can establish persistent infection in humans.  Among 
these persistent viruses, CD8+ T cell responses to EBV and CMV (herpesvirus) and HIV-1 
(lentivirus) are exceptionally well characterized.  This is due to the fact that these viruses infect a 
relatively large population of humans, and produce robust CD8+ T cell responses.  As mentioned 
in the previous section, the present methods commonly used to measure and characterize CD8+ T 
cells responses to these viruses are the MHC class I tetrameric reagent, intracellular cytokine 
staining (ICS), and ELISPOT analysis.  The MHC class I tetrameric reagent measures ex vivo 
frequency and also characterizes phenotypes (with a panel of monoclonal antibodies against 
surface markers) of virus-specific CD8+ T cells.  ICS measures ex vivo  frequency of cytokine 
producing antigen-stimulated virus-specific CD8+ T cells and also can characterize phenotypes 
of cytokine producing cells.  Likewise, ELISPOT quantitates the number of cytokines, primarily 
IFN-γ, secreting antigen-stimulated virus-specific CD8+ T cells in a given number of PBMC.   
 There are several limitations to each of these methods.  The MHC Class I tetrameric 
reagent is limited by the number of known immunodominant epitopes restricted by particular 
HLA types.  It is, also severely limited by a number of recombinant MHC class I molecules 
available.  Both functional assays, ICS and ELISPOT (measuring IFN-γ production), are limited 
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by the fact that not all the virus-specific CD8+ T cells are capable of IFN-γ production, in part 
due to functional heterogeneity (34).  Moreover, unlike ICS, ELISPOT does not allow 
phenotypic characterization of antigen-stimulated virus-specific CD8+ T cells.  Notably, to offset 
all the limitations, most recent studies use at least two of these assays, typically a combination of 
the MHC class I tetrameric reagent with either ELISPOT or ICS.  It is also possible to combine 
the MHC class I tetrameric reagent and ICS in a single assay (35).   
 
1. Responses to Epstein-Barr Virus Infection 
EBV is a member of a gamma-herpesvirus family, and establishes both lytic and persistent 
infections in human (36).  There are two strains of EBV, EBV-1 and EBV-2, in the human 
population.  In North America and Europe, seroprevalence of EBV-1 reaches over 90%, whereas 
less than 10% of the population is infected with EBV-2 (37).  While EBV infection does not 
cause significant morbidity and mortality, primary infection with EBV especially in adolescents 
and adults can occasionally result in a relatively severe clinical condition known as infectious 
mononucleosis, and persistent infection is a suspected cause of several malignancies (38).  In a 
majority of cases, primary EBV infection leads to establishment of asymptomatic latent infection 
in B cells with occasional virus reactivation and replication (39).   
 EBV-specific CD8+ T cells have been well characterized with MHC class I tetrameric 
reagents, ICS and ELISPOT, though a majority of studies has been limited to CD8+ T cells 
specific for several known immunodominant EBV epitopes.  CD8+ T cell responses to 
immunodominant epitopes from EBV lytic proteins are more robust than those for latency 
proteins, hence, CD8+ T cell responses to lytic proteins are better characterized (40).   
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 Regarding the frequency of EBV-specific CD8+ T cells, it was first reported that during 
primary infection, up to 12% of CD8+ T cells (estimated by MHC class I tetrameric reagents and 
ICS) were specific for a HLA-A2 restricted epitope (GLCTLVAML) derived from a lytic 
protein, BMLF1, and surprisingly, up to 44% of CD8+ T cells were specific for HLA-B8 
restricted epitope (RAKFKQLL) derived from another lytic protein BZLF1 (41).  The 
proportions of these EBV-specific CD8+ T cells were significantly higher than values previously 
estimated by LDA (42).  Interestingly, assessment of the usage of a variable region of TCR-β 
chain (TCR-Vβ) of EBV-specific CD8+ T cells revealed a high degree of oligoclonal expansion 
(43), which was consistent with the earlier finding of a narrowly focused CD8+ T cell response to 
EBV during primary infection (44, 45).   
 The average frequency of EBV-specific CD8+ T cells (estimated by MHC class I 
tetrameric reagents) during the latency period in asymptomatic virus carriers is on the average 
6% of total CD8+ T cells (46).  The decrease in frequency of EBV-specific CD8+ T cells during 
latent infection is thought to be due to massive apoptosis of EBV-specific CD8+ T cells upon 
resolution of primary viremia (43), reminiscent of the contraction period described in the mouse 
model of virus-specific CD8+ T cells (1).  Phenotypic analysis of CD8+ T cells specific for lytic 
epitopes reveals that during primary infection, these cells uniformly display an activated 
phenotype, CCR7-CD27+CD28+/–CD45RO+ (CD45RA–) CD38+HLA-DR+, while during latent 
infection, these cells displayed a resting memory phenotype, CD45RA+CD27+CD28+/– (40, 47).  
Additionally, a comprehensive phenotypic study showed that the majority of CD8+ T cells 
specific for EBV lytic epitopes were CD27+CD28+/– Ki-67+CD38+, while during latent infection 
these cells were phenotypically enriched in a CD27+CD28+/– subset (22).   
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 In contrast, phenotypic and functional characterization of CD8+ T cells specific for EBV 
latent epitope-specific has not been as extensive.  This is largely due to limited number of 
potential epitopes available for a study, and often the frequency of EBV latent epitope-specific 
CD8+ T cells is quite low for an accurate analysis, even with a modern methodology available.  
During primary infection, the average ex vivo frequency of immunodominant EBV latent epitope 
(EBNA 3A; HLA-A2, CLGGLLTMV)-specific CD8+ T cells (estimated by the MHC class I 
tetrameric reagent or ELISPOT) is typically less than 5%,  and in many cases, frequency is well 
below the threshold of detection limit (40, 47, 48).  During latent infection, the frequency of 
EBV latent epitope-specific CD8+ T cells slightly raises but essentially remains below 3% (40, 
47).  As expected, EBV latent epitope-specific CD8+ T cells during primary infection display an 
activated phenotype (CCR7+CD45RA–(CD45RO+) much like EBV lytic epitope-specific CD8+ T 
cells, whereas during latent infection, unlike EBV lytic epitope-specific CD8+ T cells, the 
phenotype of EBV latent epitope-specific CD8+ T cells remains essentially identical (47).   
 
2. Responses to Human Cytomegalovirus Infection 
CMV is a member of the beta-herpesvirus family, and establishes both primary and persistent-
latent infection.  As with EBV, primary infection of CMV is usually asymptomatic or associated 
with mild clinical symptoms, but can cause a severe mononucleosis in normal adults (49).  
Following primary infection, CMV causes asymptomatic persistent/latent infection in healthy 
individuals.  However, in immunocompromised individuals such as bone marrow recipients and 
HIV-1 infected persons CMV infection can be associated with severe clinical manifestations (50, 
51).  The seroprevalence of CMV infection is about 50% in the North America Caucasian 
population, who remain latently infected (51); seroprevalence and latent infection can be as high 
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as 90-100% in African-Americans and Hispanic-Americans, and in resource poor countries.  
Cellular tropism of CMV is broader than EBV; CMV is found in leukocytes, epithelial cells 
(salivary glands and cervix) and PBMC (predominantly in PMNs and monocytes) (51).   
 Although recent studies have uncovered some novel epitopes (52) and found a broader 
HLA usage of an immunodominant pp65 antigen (53), most of the knowledge of CD8+ T cell 
responses to CMV infection mainly comes from elucidation of CD8+ T cell responses to HLA-
A2 or HLA-B7 restricted immunodominant epitopes (A2;NLVPMNATV, B7;TPRVTGGGAM) 
derived from the pp65 matrix protein.  During primary infection, these CMV-specific CD8+ T 
cells expand to on the average 5% of total CD8+ T cells in asymptomatic individuals, while there 
is delayed expansion of the CMV-specific CD8+ T cells in symptomatic patients (54).  
Phenotypically, these cells are predominantly of the intermediate effector phenotype (CCR7–
CD27+CD45RA–) and also express granzyme B (54); others have reported CMV-specific T cells 
to be CD27+CD28+ (22).   
 During latent infection, the frequency of CMV-specific CD8+ T cells is similar to the 
frequency found during primary infection (54), though these cells are phenotypically enriched in 
the effector stage (CD27–CD45RA+) (25) or the late memory stage (CD27–CD28–) (22).  Down-
regulation of CD27 is associated with the number of latent CMV reactivation events in vivo, and 
is largely due to expression of CD70 (a ligand of CD27) by proliferating CMV-specific CD8+ T 
cells in the presence of IL-2 (9).  Such CD27-CD70 interaction via CMV reactivation also 
regulates the size of the pool of CMV-specific CD8+ T cells.  This also explains the age-related 
increase in the frequency of CMV-specific CD8+ T cells (55, 56).  Moreover, as with EBV-
specific CD8+ T cells, oligoclonal expansion of HLA-A2 restricted pp65 epitope-specific CD8+ 
T cells has been documented (57, 58).  
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3. Responses to Human Immunodeficiency Virus Infection 
HIV-1 is a member of the lentivirus subfamily of Retroviridae, and is the etiological agent 
responsible for AIDS.  HIV-1 establishes both primary and persistent infection predominantly in 
CD4+ T cells and in other immune cells (i.e., macrophages/monocytes and dendritic cells) (59).  
Primary infection lasts typically for 12 weeks, and is characterized by an initial burst of viremia 
with a rapid but transient decrease in the CD4+ T cell counts (60).  Following primary infection, 
HIV-1 establishes an asymptomatic persistent infection; however, unlike herpesviruses, 
persistent HIV-1 infection is not latent but progressive; viral replication continues predominantly 
in lymphoid organs during this asymptomatic period (61, 62).  Clinical manifestations of HIV-1 
infection appear on average 10 years after primary infection without antiviral drug intervention, 
although there are substantial differences in rate of disease progression among HIV-1 infected 
individuals (63).   
 After 20 years of intense research, the immune correlates of long-term protection of the 
host from progressive HIV-1 infection still remain elusive.  There are, however, observations 
implicating an antiviral role of HIV-1-specific CD8+ T cells.  A few earlier studies showed a 
temporal correlation between increase in frequency of HIV-1-specific CD8+ T cells and decline 
in acute viremia (64, 65).  TCR-Vβ analysis of HIV-1-specific CD8+ T cells during primary 
infection revealed marked oligoclonal expansion of some TCR-Vβ populations associated with a 
decline in viremia (66).  High levels of HIV-1-specific CD8+ T cell responses, slow decline in 
CD4+ T cell counts, and low viral load correlated in a longitudinal study (67).  Also, robust HIV-
1-specific CD8+ T cell responses were found among HIV-1 exposed yet uninfected prostitutes in 
Gambia (68, 69).  Moreover, viral escape from the CTL epitope has been implicated in 
accelerated progression to AIDS (70, 71).  More recent studies, however, showed that the 
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breadth and magnitude of the HIV-1-specific CD8+ T cell response does not correlate with long-
term non-progression (72, 73).   
 Direct evidence supporting the critical role of HIV-1-specific CD8+ T cells in controlling 
HIV-1 progressive infection comes from a nonhuman primate model of lentiviral infection.  In 
vivo depletion of CD8+ T cells and a subsequent simian immunodeficiency virus (SIV) challenge 
in rhesus macaques resulted in uncontrolled viral replication and rapid development of AIDS 
(74, 75).  The temporal association between emergence of the SIV-specific CD8+ T cell and 
clearance of SIV was clearly evident (76-78).  There are also several cases of vaccinated 
monkeys with stronger anti-viral CD8+ T cell responses that correlate with better clinical 
outcomes (79-82).   
 The mechanisms underlying CD8+ T cell mediated immunologic control of progressive 
HIV-1 infection are still incompletely understood.  The majority of studies have focused on 
immunological determinants for protection by contrasting function and phenotype of HIV-1-
specific CD8+ T cells from long-term nonprogressors and progressors.  These studies showed 
that a wider breadth and greater magnitude of HIV-1-specific CD8+ T cell responses were the 
best correlates of long-term survival  (72, 73).  However, the minimal quantitative and 
qualitative requirements for HIV-1-specific CD8+ T cell responses for long term survival have 
yet to be determined (83).   
 Recent phenotypic assessment of HIV-1-specific CD8+ T cells by tetramer staining 
techniques has addressed quantitative and qualitative aspects of HIV-1-specific CD8+ T cells.  At 
present, phenotypic correlates of long-term survival are not yet clear.  After primary infection, 
HIV-1-specific CD8+ T cells appear to be phenotypically enriched at an intermediate maturation 
stage (CD27+CD28–CD57–) (22, 84, 85).  This suggests that fully matured (effector) HIV-1-
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specific CD8+ T cells may not be necessary for long-term survival.  In contrast, a relatively 
higher proportion of late stage CD27–CD45RA+ (CD27–CD28–) HIV-1-specific CD8+ T cells 
appears to correlate with long term survival (86), suggesting that further maturation to the 
terminally differentiated effector CD8+ T cell offers better protection.   
 Functional assessment of HIV-1-specific CD8+ T cells has documented evidence for 
functional impairment.  This ranges from increased sensitivity to apoptosis (87, 88), increased 
TGF-β production (89), diminished IFN-γ production (90), decreased costimulatory molecule 
expression (91) and diminished granzyme and perforin production (92, 93).  It has been reported 
that IFN-γ production is not defective in HIV-1-specific CD8+ T cells from progressors, while 
perforin production is defective in HIV-1-specific CD8+ T cells from progressors (35, 93).  Lack 
of perforin production is primarily due to diminished proliferative capacity of the HIV-1-specific 
CD8+ T cells (93).  Loss of proliferative potential of HIV-1-specific CD8+ T cells from 
progressors appears to occur soon after primary infection is resolved; however, proliferative 
potential can be restored by addition of autologous HIV-1-specific CD4+ T cell isolated during 
primary infection in vitro (94).  This exemplifies a recurring theme of HIV-1 pathogenesis, that 
functional impairment of HIV-1-specific CD8+ T cells is related to lack of CD4+ T cell help (95).   
 In contrast, activation and expansion of some types of CD4+ T cells by progressive HIV-
1 infection can be a cause of functional impairment of HIV-1-specific CD8+ T cells.  For 
instance, regulatory CD4+ T cells (Tregs) recently found in the Foxp3 expressing CD25+ 
compartment of mice and humans constitutes a central part of a complex immunoregulatory 
network (96, 97).  Such an immunoregulatory network can be disrupted by progressive HIV-1-
infection, leading to excessive suppression of the antiviral CD8+ T cell response.  In fact, 
enriched human CD25+CD4+ T cells suppress IFN-γ production by antigen-stimulated HIV-1- 
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and CMV-specific CD8+ T cells in a dose dependent manner (98).  Intriguingly, a later study 
found restimultable memory (CD45RO+) HIV-1-specific CD25+CD4+ cells (99).  
 Another recent study (100) showed contradictory results.  A higher frequency of the 
CD45RO+CD25highCD4+ Tregs was strongly correlated with immunological markers (e.g., CD4+ 
T cell counts, viral load, and CD8+ T cell function) indicative of a positive clinical outcome.  
Oddly, this study suggests a clinical benefit of suppressing HIV-1-specific CD8+ (and CD4+) T 
cells as opposed to stimulating HIV-1-specific CD8+ (and CD4+) T cells in controlling 
progressive HIV-1 infection.  Interestingly, such clinical benefit by suppressing CD8+ T cell 
responses to HIV-1 infection has already been suggested.  Prolonged excessive stimulation of 
CD4+ and CD8+ T cells during progressive HIV-1 infection has been implicated as a primary 
cause of gradual dysregulation and eventual destruction of the host immune system (23, 101).  
Historically, because of a resemblance between HIV-1 and LCMV pathogenesis, it was 
originally argued by Zinkernagel that immune unresponsiveness to HIV-1 infection would be 
beneficial to the host (102).  Whether long-term survival from progressive HIV-1 infection 
requires immune unresponsiveness remains to be seen, however, it is known that healthy African 
green monkeys (a natural host of SIV) harbor high levels of SIV plasma viremia (greater than 
6x106 plasma RNA copies/ml), yet their immune systems remain unresponsive to SIV (103).   
 Additionally, immune control of CTL escape mutants is an equally important mechanism 
of immune protection from progressive HIV-1 infection.  CTL escape mutants emerge as a result 
of failed recognition of HIV-1-specific CD8+ T cell epitopes by either TCR or failed loading of 
such epitopes to cognate MHC class I molecules.  This is largely due to accumulation (due to 
selection) of HIV-1 pseudostrains carrying amino acid variations within the epitope created by 
an error-prone HIV-1 reverse transcriptase and continuous high virus turnover (104).  Immune 
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escape has been seen in certain epitopes during primary infection (105) and chronic infection 
(70), and clearly undermines development of a vaccine to control HIV-1 infection.  
 Containment of progressive HIV-1 infection by CD8+ T cells does not necessarily require 
cytolytic activity.  A novel non-cytolytic HIV-1 suppression by CD8+ T cells was first reported 
in 1986, and later shown to be a soluble factor(s), known as CAF, secreted from activated CD8+ 
T cells (106).  The suppression activity by activated CD8+ T cells has been demonstrated in 
rhesus monkeys infected by SIV (107), and more importantly, greater suppression is correlated 
with better clinical status (108).  Although there are numerous recent reports demonstrating 
CAF, the exact molecular nature of CAF has remained elusive.   
 
 19 
 
 
II.  
STATEMENT OF PROBLEM/SPECIFIC AIMS 
 
Understanding memory-effector differentiation of virus-specific CD8+ T cells is an essential 
component of modern immunology.  Recent technological advances in characterizing virus-
specific CD8+ T cells have generated phenotypic and functional details of memory-effector 
differentiation of these cells.  According to the current model of memory-effector differentiation, 
virus-specific CD8+ T cells undergo a series of phenotypically defined differentiation stages, and 
display phenotypic enrichment according to the virus specificity.  This model has been supported 
by results from many earlier studies.  However, more recent studies have pointed out several 
limitations in the current model.  Thus, the goal of the present Ph.D. project was to improve and 
expand on the current model of virus-specific CD8+ T cells by focusing on three significant 
issues based on the hypothesis that the most critical determinant of memory-effector 
differentiation of virus-specific CD8+ T cells is an interplay between the etiology of the virus 
infection and the host responses to such virus infection.  
 
Specific Aim 1: Assess memory-effector differentiation of Influenza A M1-specific CD8+ T 
cells based on a broad phenotypic characterization. 
The specific aim 1 is based on the hypothesis that CD27+CD28+ undifferentiated CD8+ memory 
T cells specific for non-persistent virus influenza A (Flu A) would have phenotypic markers 
associated with more differentiated (effector) phenotypes.  A primary goal of this aim is the 
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phenotypic assessment of CD8+ memory T cells specific for Influenza A virus (as a model of the 
nonpersistent virus) with an array of phenotypic markers reveals details of memory-effector 
differentiation that were not described by the current model of CD8+ T cell differentiation.  
Memory and effector cell subsets of Flu A-specific CD8+ T cells in healthy virus carriers will be 
determined by expression of memory–effector phenotypic markers (CD27, CD28, CD45RA, 
CD62L, CD94 and granzyme A) and chemokine receptors (CCR5, CCR6, CCR7, CXCR3, 
CXCR4, and CXCR5), with tetramer staining reagents specific for Flu A matrix protein 1.   
 
Specific Aim 2: Determine the functional capacity of CD62L+ central memory EBV-specific 
CD8+ T cells as a model for the most undifferentiated virus-specific CD8+ T cells.   
This specific aim is based on the hypothesis that a CD62L+ subset of EBV-specific CD8+ T cells 
includes the more mature effector-like subset that is capable of immediate cytoplasmic IFN-γ 
production upon peptide-specific stimulation in vitro.  The circulating memory CD8+ T cell can 
be divided into two functional subsets, TCM and TEM, based on their migratory, functional, and 
phenotypic characteristics. TCM is the immature memory subset characterized by expression of 
CD62L and CCR7 and lack of immediate cytoplasmic IFN-γ production.  Since a majority of 
virus-specific CD8+ T cells stained by MHC class I tetramers lack expression of CCR7, a 
CD62L+ subset is thought to represent TCM with respect to the virus-specificity.  Supporting this 
notion, the CD62L+ subset of EBV-specific CD8+ T cells is not able to immediately produce 
cytoplasmic IFN-γ.  However, this view has been challenged in a mouse model which has shown 
immediate IFN-γ production from CD62L+ virus-specific mouse CD8+ T cells.  A goal of the 
specific aim is to further investigate the functionality of virus-specific CD62L+ TCM.   
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Specific Aim 3: Investigate limited differentiation of HIV-1-specific CD8+ T cells from the 
intermediate stage to the late stage.  
This specific aim is based on the hypothesis that enrichment of HIV-1-specific T cell in the 
intermediate stage (CD27+CD28–) is due to impaired differentiation to the late/effector stage 
(CD27–CD28–).  Recent phenotypic and functions studies have shown that HIV-1-specific CD8+ 
T cells are enriched in an intermediate stage (CD27+CD28–) of memory-effector CD8+ T cell 
differentiation, in contrast to EBV-specific (early) and CMV-specific (late)-CD8+ T cells.  
However, unlike EBV and CMV, HIV-1 infection establishes chronic progressive infection 
which provides continuous presence of HIV-1 antigens.  The continuous supply of antigens 
should drive HIV-1-specific CD8+ T cells toward effector cells (resembling CMV-specific CD8+ 
T cells) unless memory-effector differentiation of HIV-1-specific CD8+ T cells (in the absence of 
CD4 help) is impaired.  The experiments described in this aim address whether HIV-1-specific 
CD8+ T cells endure impaired memory-effector differentiation.   
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III. 
ASSESS MEMORY-EFFECTOR DIFFERENTIATION OF INFLUENZA A M1-
SPECIFIC CD8+ T CELLS BASED ON A BROAD PHENOTYPIC 
CHARACTERIZATION. 
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A. ABSTRACT  
 
To define the role of memory T cells in a nonpersistent viral infection, we have delineated the 
phenotype of memory CD8+ T cells specific for influenza A virus (FluA; epitope matrix protein 
M158-66) based on expression of several memory/effector lineage markers and relevant 
chemokine receptors.  We found a majority of FluA-specific CD8+ T cells expressed CD27 and 
CD28, and variably expressed CD45RA, CD62L, CD94, and granzyme A.  A majority of FluA-
specific CD8+ T cells expressed high levels of CXCR3, and moderate levels of CCR5 and 
CXCR4, whereas a limited proportion expressed CCR7, CCR6 and CXCR5.  A phenotypic 
profile based on these observations showed that there are both immature and mature memory 
CD8+ T cells specific for FluA.   
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B. INTRODUCTION 
 
Generation of virus-specific memory CD8+ T cells appears to be a multi-stage developmental 
process, characterized by phenotypic alterations associated with changes in T cell functional and 
migratory capacity (109).  Most of our knowledge of memory CD8+ T cell differentiation is 
based on phenotypic analyses of CD8+ T cells specific for persistent viruses including 
herpesviruses and lentiviruses.  The predominant phenotype of CD8+ T cells specific for non-
persisting viruses, such as influenza A virus (FluA), has not been well characterized.   
 FluA infection causes severe acute airway infection associated with substantial mortality 
(110).  Although CD8+ T cells specific for the immunodominant FluA matrix epitope (FluM158-
66) persist after acute infection, their frequency in the circulation remains barely detectable by 
MHC class I tetrameric analysis (34, 111).  This low frequency makes it difficult to perform 
accurate multi-parametric flow cytometric analysis with FluA-specific MHC class I tetramers.  
Hence, there is a little known about the range of the phenotypic diversity of circulating FluA-
specific CD8+ T cells. 
 We have therefore determined the phenotype of FluA-specific CD8+ T cells by using 4-
color flow cytometric analysis employing HLA-A*0201 FluM1 tetramers, together with an 
extensive set of lineage/maturation markers including several chemokine receptors, from 
asymptomatic individuals.  We found that FluA-specific CD8+ T cells largely consisted of a 
phenotype of immature memory cells based on expression CD27 and CD28.  However, a 
significant proportion of FluA-specific CD8+ T cells also expressed CXCR3, CCR5, CD94 and 
granzyme A, suggesting a heterogeneous population of more mature, effector memory cells. 
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Thus, FluA-specific CD8+ T cells display degree of phenotypic profile indicative of a highly 
heterogeneous population of phenotypically mature memory and primed effector CD8+ T cells.  
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C. MATERIALS AND METHODS 
 
Study subjects and isolation of PBMC 
Nine HLA-A*0201 positive healthy volunteers (median age 52 yr, range 26-54 yr, all male 
Caucasians) were divided into two groups based on FluM1 tetramer or Epstein-Barr virus (EBV) 
BMLF1 tetramer reactivity: a FluM1 tetramer positive group (donor 01 through 06), and an EBV 
BMLF1 tetramer positive group (donor 01, and 07 through 09).  PBMC were isolated from 
heparinized blood samples by centrifugation on Ficoll-Hypaque (Sigma, St. Louis, MO) density 
gradients. Except for CD62L staining, the PBMC were immediately frozen in 10% DMSO and 
90% FCS by a controlled rate cryogenic freezer (Gordinier Electronics, Roseville, MI) and 
stored at -135 oC for later use.   
 
Antibodies and HLA-A*0201 tetramers 
The following antibodies were used: fluorescein isothiocynate (FITC)-conjugated mouse anti-
human CD27, CD28, CD62L, CD94 HLA-DR, CCR5, granzyme A, and perforin monoclonal 
antibodies (mAbs), unlabeled mouse anti-human CCR6, CXCR4, CXCR5, CXCR6 mAbs 
(Becton Dickinson, San Jose, CA), FITC-conjugated goat anti-mouse polyclonal F(ab’)2 
antibodies (DAKO, Carpinteria, CA), SPRD- conjugated goat F(ab’)2 anti-mouse mAb (Southern 
Biotechnology Birmingham, AL), FITC-conjugated mouse anti-rat polyclonal antibody 
(Jacksonimmuno, West Grove, PA), and FITC-conjugated mouse anti-human CD45RA, PE-Cy5 
conjugated mouse anti-human TCRαβ, and ECD-conjugated CD8 mAbs (Coulter-Immunotech, 
Miami, FL).  Rat anti-human CCR7 mAb (3D12) was kindly provided by Dr. Reinhold Forster 
(Max-Delbruck-Center for Molecular Medicine, Berlin, Germany). Appropriate isotype matched 
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mAbs (BD and Coulter-Immunotech, Miami, FL) in the fluorescent minus one (FMO) control 
(112) were used throughout the course of the study.   
 HLA-A*0201 EBV BMLF1280-288 (GLCTLVAML) and Flu A M158-66 (GILGFVFTL) 
tetrameric agents were obtained from NIH Tetramer Synthesis Facility.  These tetramers were 
labeled with PE, and used at a 1/50 dilution for staining 2-5x106 cells.   
 
Preparation of stained PBMC 
HLA-A*0201 restricted EBV BMLF1280-288  and Flu A M158-66 specific CD8+ T cells were 
stained as described in a protocol obtained from NIH Tetramer Synthesis Facility with a few 
modifications.  Briefly, for staining CD27, CD28, CD45RA, CD62L, HLA-DR, CD94 and 
CCR5, 2-5x106 fresh (for staining CD62L) or thawed frozen PBMC were resuspended in 50ul of 
PBS with 4% heat-inactivated fetal calf serum (FCS) and 0.1% azide, and were first stained with 
1ul of the appropriate tetramer at 4oC for 30 min.  Then, the cells were washed and incubated 
with PE-Cy5 mouse anti-human TCRαβ and ECD anti-human CD8 mAbs for 30 min at 4oC.  
Cells were fixed with 1% paraformaldehyde (PFA) and analyzed with an Elite XL flow 
cytometer (Beckman-Coulter) immediately after staining.  
 For detection of CCR6, CXCR3, CXCR4 and CXCR5, PBMC were first stained with the 
primary mAbs, washed, and incubated with goat anti-mouse antibody for 30 min 4oC.  Cells 
were then washed and blocked with 10% mouse serum (Sigma, St. Louis, MO) for 15 min at 
room temperature.  The tetramer, PE-Cy5 anti-human TCRαβ, and ECD anti-human CD8 mAbs 
were added, and subsequently the cells were fixed with 1% PFA.  For CCR7 staining, PBMC 
were first treated with 5% mouse serum for 15 min at room temperature, and then stained with 
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rat-anti CCR7 mAb for 30 min at 4oC.   The cells were then stained with FITC conjugated mouse 
anti-rat polyclonal antibody, and the rest of the procedure was done as described.  
 For intracellular staining of granzyme A and perforin, 2-5 x 106 fresh or frozen-thawed 
PBMC were first stained with the tetramer panel as described.  After the initial wash, cells were 
resuspended in 300 ul of OrthopermFix (OrthoDiagnostics, Raritan, NJ) or PermiFlow (Invirion, 
Frankfort, MI) for 60 min at room temperature.  Subsequently, the cells were washed and stained 
with anti-human granzyme A or perforin mAbs for 40 min at 4oC, fixed with 1% PFA and 
immediately read on the flow cytometer.   
 
Flow cytometric and statistical analysis 
The flow cytometer was calibrated daily for color compensation and laser fluctuation.  A 4 color 
compensation matrix was created for acquisition of tetramer stained samples and subsequent 
software compensation by singly and FMO staining PBMC from donors.  We followed a flow 
cytometic analysis for rare eventing described by Hoffman et. al. (111), and spectral 
compensation by Roderer (112).  Approximately 2 x 105 to 1 x 106 total events were collected for 
the fully stained sample and FMO isotype control (the same number of events were collected for 
both samples).  This resulted in more than 200 tetramer, CD8high and TCRαβ+ events based on a 
compounded gating scheme of Hoffman et.al. (111).  The frequencies of FluM1- and BMLF1-
specific CD8 T cells are shown in Table 1.  Data analysis and graphic representations were done 
by using FlowJo (TreeStar, Cupertino, CA).   
 The phenotypic profile was constructed as follows.  The percent marker expression of the 
tetramer positive and negative CD8+ T cells was derived by the number of events in the upper 
right (tetramer-marker double positives) or bottom right (tetramer negative (bulk CD8+ T cells)-
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marker positives) quadrant of plots divided by number of events in the bottom right quadrant or 
the bottom left quadrant of the same plots respectively.  The Student’s T test for paired samples 
was used to show significant difference (P < 0.05) in percent marker expression between 
tetramer positive and tetramer negative CD8+ T cells. Statistical analysis and graphical 
representation used JMP v5.0 software (JMP Sales, Cary, NC).   
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D. RESULTS 
 
Surface and intracellular expression of conventional functional and CD antigen markers on 
FluM1-specific CD8+ T cells 
To phenotypically characterize the memory-effector stage of FluM1-specific CD8+ T cells, we 
first examined expression of CD27, CD28, CD45RA, CD62L, CD94, HLA-DR and granzyme A 
(Figure. 3).  Immature and mature phenotypes were verified by the presence or absence of co-
stimulatory molecules CD27 and CD28 (14, 22), naïve (6) and central memory marker (1) 
CD62L, and effector cell markers, granzyme A (113) and perforin (114).  We found that a 
majority of FluM1-specific CD8+ T cells expressed CD27 (median 98%, range 58-100%) and 
CD28 (median 90%, range 58-100%) (Table 2), though a moderate proportion of FluM1-specific 
CD8+ T cells expressed the naïve cell/central memory marker, CD62L (median 40%, range 28-
69%) (Table 2).  Granzyme A expression was found in a relatively larger proportion of FluM1-
specific CD8+ T cells (median 63%, range 20-98%), although limited expression was seen in 
most of a lower FluM1-specific CD8+ T cells (median 16 %, 4-68%) (Table 2).  
 CD45RA expression has been found on both naïve and effector, bulk CD8+ T cells (113), 
and CD27-CD45RA+ has been shown to be an effector phenotype (19).  We observed that a 
small proportion of FluM1-specific CD8+ T cells (except subject 02) expressed CD45RA 
(median 7%, 1-14%) (Table 2).  Thus, a majority of FluM1-specific CD8+ T cells appear to be 
CD27+ CD45RA-, indicating that FluM1-specific CD8+ T cells do not display an effector 
phenotype.   
 In addition, we assessed CD94 expression, because of its known association with 
terminal differentiation (115, 116), and HLA-DR, a late activation marker (117).  A relatively 
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higher proportion of FluM1-specific CD8+ T cells expressed CD94 (median 53%, range 11-82%) 
whereas a consistently lower proportion of FluM1-specific CD8+ T cells expressed HLA-DR 
(median 14%, range 1-20%) (Table 2).   
 In summary, the phenotype of the majority of FluM1-specific CD8+ T cells circulating in 
asymptomatic donors appears to be CD27+CD28+CD45RA-HLA-DR-, and a moderate proportion 
of FluM1-specific CD8+ T cells express, CD62L, CD94 and granzyme A.  
 
Surface expression of chemokine receptors on FluM1-specific CD8+ T cells 
To further delineate memory and effector phenotypes among FluM1-specific CD8+ T cells, we 
determined surface expression of 6 chemokine receptors: CXCR3, CXCR4, CXCR5, CCR5, 
CCR6 and CCR7 (Figure 4).  CXCR4 appears to be expressed preferentially on naïve CD8+ T 
cells (118, 119); in contrast, expression of CCR5 or CXCR3 is known to be associated with 
activated memory cells (118).  CCR5 also appears to be expressed primarily on the late memory 
to effector stage of viral-specific CD8+ T cells (120).  Thus, these latter two chemokine receptors 
serve as potential mature memory/primed effector markers.  We found that moderate proportion 
of FluM1-specific CD8+ T cells expressed CCR5 (median 43%, range 20-92%), and higher 
proportion expressed CXCR3 (median 84%, range 32-99%), whereas there was a variable 
proportion of CXCR4 expression (median 45%, range 19-97%) (Table 2).   
 A previous report showed that expression of CCR6 was restricted to the memory subset 
(CD45RO+) of CD8+ T cells (121). In contrast, we found that CCR6 was minimally expressed on 
FluM1-specific CD8+ T cells (median, 5%, range 2-18%) (Table 2).   
 The expression of CCR7 differentiates CCR7+ central memory T cells and CCR7- 
effector/memory T cells (20).  We found a lower proportion of CCR7 expression on FluM1-
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specific T cells (median 20%, range 2-33%) (Table 2).  A similar, low level of CCR7 expression 
has been observed in HIV-specific and CMV-specific CD8+ T cells (25, 122, 123).  
 Thus, our data show that a large proportion of FluM1-specific, memory CD8+ T cells 
express moderate levels of chemokine receptors CCR5, CXCR3 and CXCR4 while lacking 
major expression of CXCR5, CCR6 and CCR7 receptors.  These T cells fit the conventional 
definition of memory/effector cells based on chemokine receptor expression. 
 
Comparison of the phenotypic profile between FluM1- and BMLF1-specific CD8+ T cell  
We next determined the extent of FluM1-specific CD8+ T cell maturation in relation to bulk 
CD8+ T cells.  For this, we constructed the phenotypic profile by comparing differences in the 
percent marker expression on tetramer positive CD8+ T cells and corresponding tetramer 
negative CD8+ T cells (bulk CD8+ T cells).  Then, we compared the phenotypic profiles of 
FluM1-specific CD8+ T cells to BMLF1-specific CD8+ T cells (Table 3) as an example of more 
mature CD8+ T cells.  As expected, expression of early stage memory markers (CD27, CD28, 
CD62L, CCR7 and CXCR4) on FluM1-specific CD8+ T cells was favored in the bulk CD8+ T 
cells more than in BMLF1-specific CD8+ T cells, whereas expression of some more mature 
memory markers (HLA-DR, granzyme A, and CCR5) was slightly more extensive in BMLF1-
specific CD8+ T cells (Figure. 5).  Furthermore, FluM1-specific CD8+ T cells displayed a higher 
degree of a skewed CD45RA- phenotype (from the bulk CD8+ T cells) than BMLF1-specific 
CD8+ T cells (Figure. 5).  In contrast, except for CD45RA, CD94 and CXCR3, there were no 
statistically significant differences in percent marker expression between FluM1 specific CD8+ T 
cells and bulk CD8+ T cells.  These data suggest that BMLF1-specific CD8+ T cells are skewed 
toward a more mature phenotype than FluM1-specific CD8+ T cells.   
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E. DISCUSSION 
 
In the present study, we characterized phenotypes of FluM1-specific CD8+ T cells for a large 
number of phenotypic markers and chemokine receptors.  Our data show that FluM1-specific 
CD8+ T cells appear to be CD27+CD28+CD45RA-.  This phenotypic enrichment is suggestive of 
a less mature or early stage of memory-effector cells.  Consistent with our findings, the only 
other phenotypic study on the FluM1-specific CD8+ T cell has recently shown that circulating 
FluM1-specific CD8+ T cells (CD28+CCR7-CD45RA-/low) are less mature than that of the CD8+ 
T cell specific for persistent virus infection (115).   
 Our analysis shows only slight differences in marker expression between FluM1-specific 
and BMLF1-specific CD8+ T cells despite well known, distinct differences in underlying viral 
infection and persistent antigen burden.  This is not surprising since EBV-specific CD8+ T cells 
have been shown to be phenotypically enriched in the early stage of CD8+ T cells maturation 
(22). However, persistent EBV infection causes repeated stimulation of BMLF1-specific CD8+ T 
cells, and this undoubtedly drives BMLF1-specific CD8 T cells to skew towards more mature 
phenotype than FluM1-specific CD8+ T cells.  This may reflect our observation that although 
BMLF1-specific CD8+ T cells show a greater degree of down-modulation of early stage memory 
markers (CCR7, CD28, CD62L and CXCR4), FluM1-specific CD8+ T cells appear to show the 
similar degree of differences in the percent of some effector markers (perforin, CCR5 and 
CXCR3) from the bulk CD8+ T cells.  Thus, it is possible that down-modulation of some 
phenotypic markers such as CD27 and CD28 may not be strongly correlated with development 
of effector cell phenotype.   
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 Expression of effector and activation markers could also be modulated by the nature of 
viral infection rather than memory CD8+ T cell maturation.  For instance, preferential CD94 
expression on FluM1 specific CD8+ T cells may have little to do with terminal differentiation of 
such cells.  Possibly, expression of the CD94-NKG2A heterodimer averts over-activation of 
FluM1-specific CD8+ T cells to prevent a fatal pulmonary edema due to acute infection.  Such 
regulation is presumably not necessary for persistent EBV infection.  Similarly, persistent EBV 
infection appears to cause constitutive activation of a small number of antigen specific CD8+ T 
cells, indicated by a higher proportion of HLA-DR+ BMLF1-specific CD8+ T cells.  
 In conclusion, the present study shows that circulating FluM1-specific CD8+ T cells are 
composed of multiple subsets, each displaying a distinct set of naïve, memory and effector 
markers.  Conceivably, such multiple subsets could be generated as a result of the antigen-
specific CD8+ T cell maturation (5), or they could simply signify subsets with distinct migratory 
and functional capacities.  These results suggest that phenotypic maturation may not always 
accurately ascribe functional maturation.  
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Table 1. Frequency of BMLF1 and FluM1 tetramer positive cells detected ex vivo  in peripheral 
blood.   
 
 
Antigen Donors   Tetramer Frequency *  
(%TCRαβ+ CD8+)  
 
FluM1 01   0.16 
 
02   0.13 
 
03   0.23 
 
04   0.56 
 
05   0.11 
 
06   0.14 
 
BMLF1 01   4.91 
 
07   0.40 
 
08   0.32 
 
09   1.08 
 
 
 
* Average frequency of FMO isotype control; 01 BMLF1(n=7, stdev=0.36), 01 FluM1(n=7, stdev=0.03), 
02 BMLF1(n=7, stdev=0.09), 03 BMLF1(n=6, stdev=0.05), 04 BMLF1 (n=7, stdev=0.06) 05 FluM1 
(n=8, stdev=0.02), 06 FluM1 (n=10, stdev=0.02), 07 FluM1 (n=7, stdev=0.05), 08 FluM1 (n=7 
stdev=0.01), and 09 FluM1 (N=5, stdev=0.05). 
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Figure 3. Surface and intracellular expression of memory/effector markers on BMLF1- or 
FluM1-specific TCRαβ CD8+ cells 
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Figure 4. Surface expression of chemokine receptors on BMLF1- or FluM1-specific TCRαβ 
CD8+ cells.  
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Figure 5. Comparison of the proportion of marker expression between tetramer+ and tetramer¯ 
(bulk) CD8+ T cells 
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H. Addendum  
 
In vitro stimulation and intracellular IFN-γ  staining 
In vitro peptide-specific stimulation and detection of intracellular IFN-γ production by the 
antigen specific CD8+ T cells from the thawed frozen specimen was based on a protocol obtained 
from L. Gamadia (Academic Medical Center, Amsterdam; personal communication).  Briefly, 
frozen PBMC were thawed carefully and placed in a 37oC incubator for 20min.  After washing, 
2-3 x 106 cells were resuspended in 200ul fresh RPMI medium (GIBCO/Invitrogen, Grand 
Island, NY) containing 10% FCS, and immediately treated with 10uM of appropriated peptide, 
50ng/ml PMA and 1ug/ml ionomycin, or DMSO alone.  After an hour of incubation, 5ug/ml of 
brefeldin A was added and the cells were further incubated for 5 hours.  The cells were then 
washed once with medium, and stained with anti-human TCRαβ, and anti-human CD8 mAbs as 
described.  The cells were washed again and incubated in 300ul of PermiFlow (Invirion, 
Frankfort, MI) overnight at room temperature.  After incubation, the cells were washed and 
incubated with FITC-conjugated anti-human IFN-γ and PE conjugated anti-human CD69 mAbs 
for 40 min at 4oC, washed, and fixed in 1% PFA.  
 To determine proportions of functional cells, we assessed antigen-specific intracellular 
IFN-γ production in vitro (Figure. 6A).  The frequency of IFN-γ producing, CD69+CD8+ T cells 
in the BMLF1 peptide-stimulated group was 53% to 74% of the BMLF1 tetramer+ CD8+ T cells 
(Figure. 6B). There was a greater frequency of IFN-γ producing, CD8+ T cells (82% to100%) per 
FluM1 tetramer+CD8+ T cells.  A similar discrepancy between the frequency of the tetramer and 
intracellular IFN-γ positive cells has been reported for BMLF1-specific CD8+ T cells (124, 125). 
Development of effector functions and phenotype by antigen driven differentiation may, 
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however, be independent of the cellular aging process.  As indicated by the similar proportion of 
cytoplasmic IFN-γ producing cells in both BMLF1- and FluM1-specific CD8+ T cells, it is 
possible that FluM1-specific CD8+ T cells are functionally as mature as BMLF1-specific CD8+ T 
cells.   
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Figure 6. (A) Representative IFN-γ production by of CD69+CD8+ T cells stimulated by either 
BMFL1 or FluM1 peptide in vitro. (B) Comparison of percent IFN-γ+CD69+CD8+ T cells of 
study subjects from BMLF and FluM1 groups. 
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IV. 
 
DETERMINE THE FUNCTIONAL CAPACITY OF CD62L+ CENTRAL MEMORY 
EBV-SPECIFIC CD8+ T CELLS AS A MODEL FOR THE UNDIFFERENTIATED 
VIRUS-SPECIFIC CD8+ T CELLS. 
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A. ABSTRACT 
 
Central memory T cells (TCM) have been distinguished from effector memory T cells (TEM) by 
the presence of surface CD62L (L-selectin), and the absence of immediate effector functions 
(e.g. IFN-γ production).  However, surface CD62L is known to be proteolytically cleaved and 
rapidly shed following T cell activation, which could alter phenotypic characteristics during T 
cell stimulation.  In the present study, we show that EBV-specific CD62L+ CD8+ T cells express 
intracellular IFN-γ upon antigen-specific stimulation if activation-induced shedding of CD62L is 
circumvented. These results suggest that CD62L+ TCM have TEM capacity, and that the current 
definition of antigen-specific CD8+ TCM using lineage markers needs to be re-evaluated.  
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B. INTRODUCTION 
 
Central memory T cells (TCM) are a subset of memory T cells that lack characteristics of effector 
cells.  Two definable characteristics of TCM are co-expression of homing receptors for lymphoid 
organs, CCR7 and CD62L, and lack of immediate cytoplasmic IFN-γ production after antigen 
stimulation(20). In particular, two recent studies have shown that Epstein-Barr virus (EBV) 
specific CD62L+CD8+ T cells stimulated with EBV peptides in short-term culture do not produce 
cytoplasmic IFN-γ (124, 125).  This supports the notion that antigen-specific CD62L+ TCM lack 
immediate effector, cytokine-producing capacity.   
 Surface expression of CD62L molecules can be altered by proteolytic cleavage and 
shedding of the extra-cellular portion of CD62L after cell activation(126-129).  In the present 
study, we demonstrate that pre-enriched CD62L+CD8+ T cells produced IFN-γ after short-term 
peptide-stimulation.  Moreover, in the presence of the CD62L sheddase inhibitor, GM6001(130), 
antigen-stimulated EBV-specific CD8+ T cells contain CD62L+IFN-γ+ cells, indicating that 
CD62L+CD8+ T cells can express intracellular IFN-γ  during short-term stimulation.  These 
results suggest that use of CD62L expression and lack of immediate IFN-γ production for 
defining antigen-specific TCM and its lineage relationship to TEM need to be re-evaluated.  
 50 
B. MATERIALS AND METHODS  
 
Peptides, antibodies and HLA-A*0201 tetramers 
Two peptides GLCTLVAML (HLA-A*0201 EBV BMLF1280-288; GLC) and RAKFKQLL (HLA-
B*0801 EBV BZLF1190-197; RAK) were produced by the University of Illinois at Chicago 
Protein Research Laboratory.  Monoclonal antibodies used were fluorescein isothiocynate 
(FITC)-conjugated anti-CD62L and FITC or phycoerythrin (PE) conjugated anti-IFN-γ (Becton 
Dickinson, San Jose, CA), and PE-Cy5 anti-CD62L and PE-Cy7 anti-CD8 (Beckman-Coulter-
Immunotech, Miami, FL).  PE conjugated HLA-A*0201 EBV BMLF1280-288  tetramer was 
purchased from Immunomics (Beckman-Coulter, San Diego, CA), and HLA-B*0801 EBV 
BZLF1190-197 tetrameric agents was obtained from the NIH Tetramer Synthesis Facility.  
Tetramer staining was done at 4Co for 30 min or 37Co for 25 min as indicated in the figure 
legend.   
 
Isolation of peripheral blood mononuclear cells (PBMC), and enrichment of CD62L+ PBMC by 
magnetic beads.  
PBMC were isolated on Ficoll-Hypaque (Sigma, St. Louis, MO) density gradients.  
Approximately 20 x 106 cells were stained with FITC mouse anti-human CD62L antibody for 30 
min at 4oC.  CD62L+ cells (greater than 96% purity) were positively enriched by two rounds of 
magnetic bead separation (MACS, Miltenyl, Bergisch-Galdbach, Germany).  
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In vitro stimulation and intracellular IFN-γ staining 
Freshly donated 2-3 x 106 PBMC, and CD62L+ or CD62L¯ cell populations, were resuspended 
in 200 µl of RPMI 1640 with 10% FCS in the presence of 10uM GLC or RAK peptide.  PBMC 
were also stimulated in the presence of 200 µM GM6001 (Calbiochem, San Diego, CA) and pre-
stained with GLC or RAK tetramer (37oC for 25 min) where appropriate.  After an hour of 
incubation, 5ug/ml of brefeldin A was added and the cells were further incubated for 5 hours.  
The cells were then washed once with medium and stained with PE-Cy5 anti-CD62L, and PE-
Cy7 anti-CD8 mAbs.  The cells were washed and incubated in 300 µl of PermiFlow (Invirion, 
Kalamazoo, MI) overnight at room temperature.  Following overnight incubation, cells were 
washed and incubated with FITC or PE anti-human IFN-γ for 40 min at 4oC, and washed.   
 
Flow cytometric analysis 
Stained samples were run on a Coulter XL flow cytometer (Beckman-Coulter, Miami, FL).  Data 
analysis and graphical representations were done using FlowJo (TreeStar, Cupertino, CA).  A 
gating strategy based on the compounding gating method (111) was used throughout the study.   
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D. RESULTS AND DISCUSSION 
 
Two recent reports have provided evidence that the CD62L+ subset of EBV-specific CD8+ T 
cells does not produce cytoplasmic IFN-γ upon short-term stimulation(124, 125).  Other studies, 
however, have shown that PMA and ionomycin-stimulated, bulk CD62L+CD8+ T cells(130), and 
antigen-stimulated CCR7+ virus-specific CD8+ T cells produce IFN-γ (29).  To address this 
discrepancy, PBMC were stimulated with GLC or RAK peptides for 6 hours, followed by 
intracellular staining for IFN-γ.  Although nearly 50% of GLC- and 37% of RAK-specific CD8+ 
T cells expressed surface CD62L (Figure 7A), IFN-γ production was not associated with CD62L 
expression (Figure 7B).  This is in accordance with the observations made by Tussey et.al (125), 
and Hislop et.al (124).  
 Surface CD62L molecules can be rapidly cleaved and shed following cell activation(126-
129).  Enrichment of CD62L+CD8+ T cells prior to peptide-specific stimulation will circumvent 
CD62L shedding, and demonstrate immediate IFN-γ production by CD62L+ GLC or RAK-
specific CD8+ T cells.  As shown in Figure 7C, peptide stimulated, CD62L pre-enriched, GLC- 
and RAK-specific CD8+ T cells produced IFN-γ during short-term culture. 
 To further circumvent activation-induced CD62L shedding, bulk CD8+ T cells were 
stimulated with specific peptides in the presence or absence of GM6001, a CD62L sheddase 
inhibitor (130).  Treatment of the cells with 200uM of GM6001 significantly inhibited shedding 
of surface CD62L without affecting IFN-γ production, clearly demonstrating immediate 
cytoplasmic IFN-γ production in over 50 % of GLC- and RAK-specific CD62L+CD8+ T cells 
(Figure 8A and B).  Notably, there were also GLC- and RAK-specific CD62L+CD8+ T cells that 
did not express IFN-γ in response to antigen-specific stimulation.  
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 Recently, CD62L+CD8+ T cells stimulated with PMA and ionomycin were shown to 
produce several cytokines including IFN-γ (130).  Moreover, antigen-stimulated CCR7+ viral-
specific CD8+ T cells were able to produce immediate IFN-γ and TNF-α (29), and antigen-
stimulated EBV-specific TCM  (CD45RAlowCCR7dull) produced IFN-γ  and IL-2 (131).  Even 
naïve CD8+ T cells have the capacity to produce IFN-γ although such cells require longer 
stimulation (132).  These observations suggest that TCM have the capacity for immediate IFN-γ 
production.  
 Our data demonstrated that antigen-specific CD62L+ TCM have immediate effector 
function (Figure 8C).  Apparently, CD62L-CD8+ TEM are able to re-express surface CD62L as 
long as CD62L transcription is not permanently silenced (109).  Indeed, murine TCM (CD62L+ 
CCR7+) can evolve directly from a surviving fraction of CD62Llow TE/EM (1).  Presumably, such 
CD62L+ TCM retain the capacity for immediate effector function including immediate IFN-γ 
production following antigenic stimulation.  This explains the capacity of CD62L+ EBV-specific 
CD8+ T cells to produce immediate IFN-γ upon antigenic stimulation.  However, the presence of 
IFN-γ negative CD62L+ EBV-specific CD8+ T cells in our study suggests that CD62L+ TCM have 
more than one functional subset.  Potentially, these cells may represent CD62L+ TCM that have 
remained undifferentiated, or become dysfunctional (Figure 8C).  
 In conclusion, we show that over 50% of CD62L+CD8+ T cells specific for EBV antigen 
can produce cytoplasmic IFN-γ. Our results suggest that CD62L and immediate IFN-γ 
expression is not confined to either TCM or TEM but is broadly expressed among various memory 
CD8+ T cell subsets.  Thus, a further refinement of functional and phenotypic definitions and 
lineage relationships between TCM and TEM is needed.  
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Figure 7. (A) Visualization of CD62L+ TCM subset of GLC (A2 BMLF1)- and RAK(B8 
BZLF1)specific CD8+ T cells. (B) GLC and RAK-specific CD62L+ cells in bulk CD8+ T cells 
did not produce cytoplasmic IFN-γ following peptide stimulation. (C) GLC- and RAK-specific 
CD62L+ cells in enriched produced cytoplasmic IFN-γ following peptide stimulation 
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Figure 8. (A) GLC-stimulated CD62L+ GLC tetramer-specific CD8+ T cells produce cytoplasmic 
IFN-γ in the presence of GM6001. (B) RAK-stimulated CD62L+ RAK tetramer-specific CD8+ T 
cells produce cytoplasmic IFN-γ in the presence of GM6001. (C) A schematic diagram depicting 
two distinct lineages of TCM. 
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V. 
 
INVESTIGATE LIMITED DIFFERENTIATION OF HIV-1-SPECIFIC CD8+ T CELLS 
FROM THE INTERMEDIATE STAGE TO THE LATE STAGE. 
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A. ABSTRACT  
 
HIV-1-specific CD8+ T cells play a major role in controlling acute HIV-1 viremia, however, 
these cells appear to eventually lose control of chronic infection.  Failed control of chronic HIV-
1 infection by HIV-1-specific CD8+ T cells could be due to their inability to undergo memory-
effector differentiation.  In the present study, we used 6-color flow cytometric analysis to 
establish a detailed phenotypic assessment of HIV-1-specific CD8+ T cell memory-effector 
differentiation by analyzing expression of CD27, CD28, CD57, and CD62L and by comparing 
phenotypes of EBV- and CMV-specific CD8+ T cells as models of an immature memory and a 
mature effector CD8+ T cells respectively.  We found that HIV-1-specific CD8+ T cells were 
phenotypically enriched in a late intermediate stage of CD8+ T cell differentiation (CD27+CD28–
CD57–/lowCD62L–).  Moreover, unlike EBV- and CMV-specific CD8+ T cells, HIV-1-specific 
CD8+ T cells did not display memory-effector differentiation associated down-regulation of 
CD27 and CD28 and up-regulation of CD57.  Furthermore, these cells showed a comparably 
smaller proportion of a CD27–CD57high terminally differentiated effector subset.  These results 
suggest that despite the continuous presence of viral antigen, HIV-1-specific CD8+ T cells do not 
complete normal CD8+ T cell memory-effector differentiation.   
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B. INTRODUCTION 
 
Assessing memory-effector differentiation of virus-specific memory CD8+ T cells is essential to 
understand how virus-specific memory CD8+ T cells are able to contain viral infection.  Distinct 
stages of CD8+ T cell differentiation can be assessed phenotypically based on expression of 
several phenotypic markers that are known to be up- or down-regulated during the natural course 
of CD8+ T cell memory-effector differentiation.  Currently, virus-specific memory CD8+ T cells 
are shown to progress from the least mature stage of CD27+CD28+CD45RO+,  to the more 
mature (effector) stage of CD27–CD28–CD45RA+ (23, 32).  The most mature or terminally 
differentiated effector cells can be further defined by expression of CD57 (88).   
 Recent phenotypic assessment based on these phenotypic markers has shown that virus-
specific memory CD8+ T cells display phenotypes that are associated with particular stages of T 
cell memory-effector differentiation depending on the nature of viral infection.  Memory CD8+ T 
cells specific for non-persistent virus such as influenza A virus show less differentiated memory 
phenotype (CD27+CD28+CD45RO+) (115, 133).  In contrast, CD8+ T cells specific for persistent 
viruses such as EBV and CMV show a further differentiated phenotype, characteristic of mature 
memory (CD27+CD28+/–CD45RO+) and effector (CD27–CD28–CD45RA+) subsets, respectively 
(23, 32).   
 One of the critical factors that drives differentiation of CD8+ T cells appears to be 
repeated antigen exposure.  Unlike herpes viruses, HIV-1 replicates continuously providing a 
constant supply of HIV-1 antigens, hence, long-term HIV-1 infection theoretically drives HIV-1-
specific CD8+ T cells to terminal differentiation.  While the dominant phenotype of HIV-1-
specific CD8+ T cells for long-term non-progressors has been shown to be the effector subset 
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(CD27–CD45RA+) (86), others have reported that the phenotype of the HIV-1-specific CD8+ T 
cell remains essentially the same (CD27+CD28–) regardless of clinical status (85) and duration of 
infection (84).  Thus, HIV-1-specific CD8+ T cell memory-effector differentiation during the 
natural course of CD8+ T cell maturation remains to be clarified.   
 In the present study, we assessed memory-effector differentiation of HIV-1-specific 
CD8+ T cells by a refined phenotypic analysis based on 6-color flow cytometry.  We found that 
unlike EBV- and CMV-specific CD8+ T cells, HIV-1-specific CD8+ T cells do not exhibit 
maturation associated regulation of CD27, CD28 and CD57 expression.  We also found that in 
contrast to EBV and CMV-specific CD8+ T cells, the majority of HIV-1-specific CD8+ T cells 
are phenotypically enriched with a CD27+(low)CD57low (intermediary) subset and showed an 
irregular pattern of progression from a CD27+(high)57– (memory) to CD27–CD57high (effector) 
subset.  These results suggest that the phenotypic enrichment of HIV-1-specific CD8+ T cells 
(CD27+CD28–CD57–/lowCD62L–) that persists in spite of the continuous presence of HIV-1 
antigen is due to impaired effector differentiation.   
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C. MATERIALS AND METHODS 
 
Study Population 
The study population consisted of 10 HIV-1 uninfected volunteers (median age 52 yr, range 43-
69yr, 1 female and 12 male Caucasians)  and 13 HIV-1 infected subjects (median age 48 yr, 
range 25-70 yr, all male Caucasians)  from the Pittsburgh portion of the national Multicenter 
AIDS Cohort Study (MACS).  Their HLA types are listed in Table 1.  CD4+ T cell counts and 
viral load in the HIV-1 infected subjects and status of antiretroviral therapy at the time of blood 
draw are summarized in Table 2.  HIV-1 serum viral load was assayed by a quantitative RT-PCR 
assay (Amplicor; Roche Diagnostics, Alameda, CA).  HLA-typing was done at the Laboratory of 
Genomic Diversity, National Cancer Institute and the laboratory of Dr. M. Trucco, University of 
Pittsburgh.   
 
Antibodies and Class I tetramers 
The following antibodies were used: fluorescein isothiocyanate (FITC)-conjugated mouse anti-
human CD57 and (phycoerithrin) PE-Cy5 conjugated mouse anti-human CD27 (BD Biosciences, 
San Jose, CA);  ECD (PE-Texas Red)-conjugated mouse anti human CD28 and PE-Cy7 
conjugated mouse anti-human CD8 (Coulter-Immunotech, Miami, FL); (allophycocyanine) 
APC-Cy7 conjugated mouse anti human CD62L. (Caltag, Burlingame, CA).  Appropriate 
isotype-matched mAbs were obtained from the same companies, and used throughout the course 
of the study.   
 class I tetrameric reagents used in the study were listed in Table 2.  All the tetrameric 
agents except A2pp65 CMV and A2BMLF1 EBV were obtained from NIH Tetramer Synthesis 
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Facility.  A2pp65 CMV and A2BMLF1 EBV tetramers were obtained from Coulter 
Immunomics (San Diego, CA).  All of the tetramers were labeled with PE, and used at a 1/50-
1/200 dilution for staining 2-5x106 PBMCs.   
 
Isolation and preparation of stained PBMC 
Blood specimen were collected in BD Vacutainer Cell Preparation Tubes (CPT) with sodium 
heparin (BD Biosciences, San Jose, CA), and PBMC were isolated according to the 
manufacturer’s protocol.  PBMC were stained as described previously (133).  Briefly, 2-5x106 
fresh PBMC were resuspended in RPMI 1640 (GIBCO, Grand Island, NY) with 10% heat 
inactivated fetal calf serum (FCS) (Hyclone, Logan, UT)  and were first stained with 1/50-1/200 
dilution of the appropriate tetramer at 37oC for 25 min.  Then, cells were washed and 
resuspended in PBS with 4% FCS and 0.1% sodium azide, and incubated with a cocktail of 
mAbs for 30 min at 4oC.  After the final wash, cells were fixed with 1% paraformaldehyde 
(PFA) and analyzed by an MoFlo flow cytometer (DakoCytomation, Boulder, CO).  
 
Flow Cytometry 
The MoFlo flow cytometer was calibrated daily for color compensation and laser fluctuation.  A 
6 color compensation matrix was created by FlowJo (TreeStar, Cupertino, CA) software 
compensation based on six singly stained PBMC from actual donors as recommended by 
manufacturer (TreeStar).  A PE-conjugated mouse anti-human CD8 monoclonal antibody was 
used for PE compensation in a place for the MHC class I tetramer.   
 We used a flow cytometic analysis described previously (133) with a few modifications.  
A minimum of 500 total tetramer+CD8high events were collected for the fully stained sample and 
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isotype control (the same number of events were collected for both samples), and this resulted in 
collection of approximately 1-3x106 total events.  We used a compounded gating scheme 
previously described (111) (133)with necessary modifications.  Briefly, cells were first gated on 
the CD8high population on a CD8 and SS-Log plot, followed by a lymphocyte gate on an FS and 
SS-Log plot.  Potential doublets were excluded on FS and FS-integrated (FS-int), and the 
resulting tetramer+ population was visualized on a tetramer-PE vs SSLog plot for determining 
phenotypic analysis and frequency of tetramer+CD8+ T cells.  Data analysis and graphic 
representations were done with FlowJo software (TreeStar, Cupertino, CA).   
 
Statistical analysis 
We used Whitney-Mann U, Wilcoxon Rank-Sum and Tukey-Kramer HSD tests for determining 
statistical significance between and among group means.   We used the Spearman correlation test 
and a standard least square method for determining r correlation coefficients and P values; 
P<0.05 was considered statistically significant.  Statistical analysis and graphical representation 
were done using JMP IN v5.1 (JMP Sales, Cary, NC) and Aabel software (Gigawiz LTD Co, 
Tulsa, OK).   
 65 
D. RESULTS 
 
EBV-, CMV, and HIV-1-specific CD8+ T cells show distinct levels of CD27, CD28, CD57, 
and CD62L expression.   
We first used a battery of phenotypic markers and MHC class I tetramers to assess virus-specific 
T cell phenotypes comparable to those previously related to a unique virus-specific memory 
CD8+ T cell during persistent viral infections (22).  Virus-specific CD8+ T cells were visualized 
by a host of MHC class I tetramers (Figure. 9A and Table 5), and phenotype of virus-specific 
CD8+ T cells were assessed by co-staining with antibodies against CD27, CD28, CD57, and 
CD62L (Figure. 9B).   
 Comparison of percent marker expression revealed a phenotypic subset unique to each 
virus-specific CD8+ T cells (Figure. 10A).  The major phenotypic subsets of EBV-, HIV-1-, and 
CMV-specific CD8+ T cells were CD27+CD28+CD57–CD62L+/–, CD27+CD28–CD57+CD62L–, 
and CD27–CD28–CD57+CD62L– respectively.  These data suggest that EBV-specific CD8+ T 
cells display the least differentiated phenotype (central memory), while CMV-specific CD8+ T 
cells display the most differentiated phenotype (effector).  HIV-1-specific CD8+ T cells appear to 
be phenotypically in an intermediate stage of CD8+ T cell differentiation.  This is in agreement 
with observations made by Appay, et al. (22).   
 A few HIV-1 infected subjects (Table 4) had either or both EBV- and/or CMV-specific 
CD8+ T cells, making it possible to compare phenotypes of three virus-specific CD8+ T cells 
from the same immunological background. EBV- and CMV-specific CD8+ T cells showed a 
similar pattern of percent CD27, CD28, CD57, and CD62L expression as compared to HIV-
specific CD8+ T cells from the same HIV infected subjects (Figure. 10B).  Moreover , we found 
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no statistical differences (p>0.05) in percent marker expression of EBV- and CMV-specific 
CD8+ T cells between HIV-1 uninfected and infected subjects as predicted (Figure. 11A and B).   
 These differences can be attributed to equally skewed proportions of bulk CD8+ T cells 
(tetramer– CD8+ T cells) expressing these markers from HIV-1 infected subjects.  Although bulk 
CD8+ T cells from HIV-1 infected subjects show a relatively lower proportion of CD27 and 
CD62L and higher proportion of CD57 expressing T cells, only the proportion of CD28+ T cells 
was significantly different from that of HIV-1 uninfected subjects (Figure. 11C).   
 These data suggest that even though HIV-1 infection affects expression of at least one 
marker (CD28) in bulk CD8+ T cells, such impairment does not appear to significantly skew 
memory-effector differentiation of EBV- and CMV-specific CD8+ T cells.   
 
HIV-1-specific CD8+ T cells do now show correlations among percent marker expression, 
and correlations between percent marker expressions and frequency. 
We next examined correlations between percent marker expression of the virus-specific CD8+ T 
cells to determine whether there is a memory-effector differentiation-associated modulation of 
these phenotypic markers.  If the virus-specific CD8+ T cell undergoes uninterrupted memory-
effector differentiation, such a correlation would be expected especially between CD27 and 
CD28 expression. This is based on the known dichotomy of their differential expression during 
memory-effector CD8+ T cell differentiation (22).  Both EBV- and CMV-specific CD8+ T cells 
showed a significant positive correlation between percent CD27 and CD28 expression 
(EBV:R=0.81, p<0.05, CMV:R=0.87, p<0.0001), whereas there was not correlation for any 
combination of phenotypic markers on HIV-1-specific CD8+ T cells (Figure. 12).  In addition,  
there were significant correlations for EBV-specific CD8+ T cells between CD27 and CD57 
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(R=0.81, p<0.05), and CD28 and CD57 (R=0.97, p<0.001).  Similarly, CMV-specific CD8+ T 
cells show significant correlations between CD27 and CD62L (R=0.58, p<0.05), and CD28 and 
CD62L (R=0.62, p<0.01).   
 We next examined correlations between the frequency of the virus-specific CD8+ T cells 
and percent marker expression (Figure. 13).  EBV- and CMV-specific CD8+ T cells displayed a 
significant correlation between percent CD27 expression and frequency (EBV: R=0.86, p<0.02, 
CMV:R=0.55, p<0.05).  In addition, CMV-specific CD8+ T cells showed significant correlations 
between percent and frequency of CD28 and CD62L expression (CD28: R=0.48, p<0.05, 
CD62L: R=0.55, p<0.05).  In contrast, HIV-1-specific CD8+ T cells did not show any significant 
correlations for expression or frequency of any of the markers.   
 These results show that coordinated down-modulation of CD27 and CD28 expression is 
the most consistent phenotypic marker alteration associated with  memory-effector 
differentiation, based on EBV- and CMV-specific CD8+ T cells from HIV-1 uninfected subjects.  
Also, memory-effector CD8 T cell differentiation of HIV-1-specific CD8+ T cells appears to be 
arrested at a stage of CD27 down-modulate.  Alternatively, these results indicate a possible 
deletion of a CD27– subset of HIV-1-specific CD8+ T cell.   
 
HIV-1-specific CD8+ T cells are enriched in the CD27–CD57+(high) subset and do not appear 
to display transition from CD27+(high)CD57– to CD27–CD57+(high).    
It is possible that majority of HIV-1-specific CD8+ T cells differentiated into effector cells 
without down-regulating CD27 expression.  To address this, we examined CD57 expression as 
an additional marker of the effector phenotype.  In agreement with results from previous 
sections, relative phenotypic enrichment based on CD27 and CD57 expression of virus-specific 
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CD8+ T cells indicates that HIV-1-specific CD8+ T cells are accumulated in intermediate stage 
(CD27+CD57+) of memory-effector differentiation.  Likewise, EBV-specific CD8+ T cells are 
enriched in undifferentiated memory stage (CD27+CD57-), and CMV-specific CD8+ T cells are 
enriched in terminal effector stage (CD27–CD57+) (Figure. 15).   
 EBV- and CMV-specific CD8+ T cells appear to uninterruptedly progress from 
CD27highCD57– (undifferentiated memory) to CD27lowCD57low (transitional stage), and finally to 
CD27–CD57high (effector) (Figure. 14B).  This pattern of progression from immature to mature 
states becomes more apparent in the relatively more differentiated EBV-specific CD8+ T cells 
(Figure. 14B 1) and generally in most of the CMV-specific CD8+ T cell (Figure. 14B 2).  Even 
EBV- and CMV-specific CD8+ T cells from the same HIV-1 infected individuals show a similar 
pattern (Figure. 14B 4).  However, a majority of HIV-1-specific CD8+ T cells (Figure. 14B 3 and 
4) seldom display such pattern, even for some HIV-1-specific CD8+ T cells with relatively well 
developed CD27–CD57+ subset (Figure. 14B 5).  Based on these results, HIV-1-specific CD8+ T 
cells appear to be enriched in the transitional stage (CD27highCD57low), and do not appear to 
differentiate to the effector subset (CD27–CD57–) even during chronic, untreated HIV-1 
infection.   
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E. DISCUSSION 
 
Recent 4-color phenotypic studies characterizing HIV-1-specific CD8+ T cells have shown that 
these cells are phenotypically enriched in the intermediate stage of memory-effector CD8 T cell 
differentiation, relatively more differentiated than immature EBV-specific CD8+T cells and less 
differentiated than effector CMV-specific CD8+ T cells (22, 84-86).  In agreement with these 
studies, our 6-color study showed that the majority of HIV-1-specific CD8+ T cells, regardless of 
clinical status of the HIV-1 infected study subjects, displayed the phenotype (CD27+CD28–
CD57–/lowCD62L–). This is indicative of the advanced intermediate stage of memory-effector 
differentiation as compared to the average phenotype of EBV-specific CD8+T cells 
(CD27+CD28+CD57–CD62L+/–) and of CMV-specific CD8+ T cell (CD27–CD28–
CD57low/highCD62L–) (Figure. 15) .   
 If memory-effector differentiation of the antigen-specific CD8+ T cell depends primarily 
on the antigen load, progressive HIV-1 infection, unlike predominately latent EBV and CMV 
infection, would provide continuous presence of HIV-1 antigens that in theory should drive HIV-
1-specific CD8+ T cells to be more differentiated effectors.  However, HIV-1-specific CD8+ T 
cells remain largely less differentiated than CMV-specific CD8+ T cells.  Our results favor the 
possibility that an impaired immune system caused by progressive HIV-1 infection has a 
negative impact on memory-effector differentiation of HIV-1-specific CD8+ T cells.  One could 
argue that such immune impairment would affect differentiation of any antigen-specific CD8+ T 
cells. However, our data show that EBV- and CMV-specific CD8+ T cells from HIV-1 infected 
individuals display similar phenotypic enrichment to T cells from HIV-1-uninfected individuals.  
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This strongly suggests that immune impairment posed by progressive HIV-1 infection appears to 
predominately affect differentiation of HIV-1-specific CD8+ T cells.   
 Evidence supporting impaired differentiation of HIV-1-specific CD8+ T cells has been 
documented (32), though the proposed underlying mechanism of such impairment remains 
largely speculative.  A possible mechanism provided by our data is that HIV-1-specific CD8+ T 
cells lose the capacity to undergo differentiation from the advanced intermediate stage 
(CD27highCD57low) to the effector stage (CD27–CD57high), potentially due to inability to down-
regulate CD27.  It has been shown that CD27 down-regulation on CMV-specific CD8+ T cells 
requires CD70 expression induced by antigen-specific activation (or activation through the T cell 
receptor-CD3 complex) and the presence of IL-2 (9).  Thus, long-term continuous activation of 
HIV-1-specific CD8+ T cells in the absence of IL-2 due to CD4+ T cell loss possibly causes HIV-
1-specific CD8+ T cells to fail to down-regulate CD27.   
 Alternatively, the effector subset (CD27–CD57high) of HIV-1-specific CD8+ T cells may 
have developed but was depleted during chronic HIV-1 infection.  This is possible considering 
the fact that CD57+CD8+ T cells are more prone to activation-induced apoptosis (88).  Also, 
chronic antigen stimulation could prolong CD27-CD70 interaction due to over expression of 
CD70 on HIV-1-specific CD8+ T cells (134).  However, in the absence of CD28, co-stimulation 
through CD27 is sufficient for survival of effector T cells in mice (135).  Similarly, antigen-
specific stimulation of CD27+ HIV-1-specific CD8+ T cells with CD27 co-stimulation results in 
prolonged survival of proliferating cells (136).  Thus, it appears that excessive CD27-CD70 
interaction may lead to generation and subsequent deletion of CD27–CD57high HIV-1-specific 
CD8+ T cells.  This may explain the relatively lower range of frequency of HIV-1-specific CD8+ 
T cells observed in our study. Also, the average frequency of HIV-1-specific CD8+ T cells (in 
 71 
total CD8+ T cells) is estimated to be around 0.1%-1% (137), although higher frequencies (over 
5%) of HIV-1-specific CD8+ T cells have been found occasionally by tetramer staining (85) and 
ELISPOT and intracellular IFN-γ staining (138).   
 It is not entirely clear whether a particular phenotypic enrichment or differentiation stage 
of the virus-specific CD8+ T cells can provide necessary and sufficient protection from the virus 
infection.  Intuitively, having a large proportion of effector virus-specific CD8+ T cells seems to 
be advantageous because of their capacities to mount immediate protection with direct cytotoxic 
functions.  However, having a large proportion of effector cells may not be suitable for long-term 
protection if effectors readily undergo activation-induced apoptosis.  This issue has remained 
controversial in the context of assessing phenotypic correlates of long-term survival in HIV-1 
infection (23, 32).  The mode of long-term nonprogression can be multifaceted, with HIV-1 
infected individuals including long-term survivors being heterogeneous in their current and 
previous clinical conditions (e.g., viral load, CD4+ T cell counts, duration of infection, types of 
medications) and basis of immune control of HIV-1 infection.   
 Our study shows that HIV-1-specific CD8+ T cells from a cross section of HIV-1 infected 
individuals show remarkably consistent phenotypes, despite of a range of clinical status.  Our 
observations are in agreement with those of Papagno et. al. (85) that long-term progressive HIV-
1 infection, regardless of clinical conditions, does not considerably skew phenotypic enrichment 
of HIV-1-specific CD8+ T cells.   
 In conclusion, we assessed the state of memory-effector differentiation of HIV-1-specific 
CD8+ T cell by characterizing and comparing phenotypes of HIV-1-, EBV-, and CMV-specific 
CD8+ T cells based on 6-color, 8-parameter flow cytometry.  We found that HIV-1-specific 
CD8+ T cells predominantly displayed the phenotype (CD27+CD28–CD57lowCD62L–) 
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characteristic of the advanced intermediate stage of CD8+ T cell memory-effector differentiation.  
Moreover, we noted that some EBV- and majority of CMV-specific CD8+ T cells displayed 
coordinated modulation of CD27, CD28, and CD57 expression during memory-effector 
differentiation, while a majority of HIV-1-specific CD8+ T cells did not.  Particularly, HIV-1-
specific CD8+ T cells did not demonstrate differentiation to the effector subset (CD27–CD57high).  
These results indicate HIV-1-specific CD8+ T cells sustain impaired effector differentiation, or 
alternatively this effector subset could be deleted during the course of progressive HIV-1 
infection.   
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Table 4. HLA types, tetramer reactivity, and clinical data of study subjects 
 
Subjects  HLA type    Tetramer reactivitya         Clinical statusb  CD4 countsc Viral loadd 
1. A2, A3, B27, B37 A2p17, A2pol, A2CMV HIV-1+, no HAART 459 939 
  A2EBV 
2. A3, A24, B27, B15 A3p17, A3pol HIV-1+, noHAART  385   24968 
3. A1, A32, B40, B8 B8p24, B8Nef HIV-1+, no HAART 270   18646 
4.  A2, A26, B44, B15 A2p17, A2CMV HIV-1+, HAART 457 50 
5. A1, A32, B8, B40 B8p24 HIV-1+, HAART 483 50 
6.  A2, A33, B15, B42 A2p17 HIV-1+, no HAART 1029 101 
7. A2, A2, B27, B13 A2p17, A2pol, A2EBV, HIV-1+, no HAART 990 23737 
  A2CMV 
8. A3, A31, B13, B51 A3p17 HIV-1+, no HARRT 453 22580 
9. A2, A3, B57, B40 A2p17, A2pol, A3p17, A3pol, HIV-1+, no HARRT 129  66752 
  A2EBV, A2CMV 
10. A2,  A2CMV HIV-1– 
11.  A2, A2, B8 A2EBV, B8EBV HIV-1– 
12.  A2, A31, B15, B44 A2CMV HIV-1– 
13. A2, A24, B44, B7 A2EBV, A2CMV HIV-1– 
14. A2,  A2EBV, A2CMV HIV-1– 
15. A1, A2, B8, B56 A2CMV HIV-1– 
16. A1, A11, B8, B15 B8EBV HIV-1– 
17. A1, A2, B18, B51 A2EBV, A2CMV HIV-1– 
18. A2, A23, B13, B44 A2CMV HIV-1– 
19. A2, A23, A39, B41 A2CMV HIV-1– 
 
a Each tetramer is designated by the HLA-type and the antigen.  See table 2. for more detail on tetramer designation.   
b Clinical status of study subjects at the time of their blood draw. HIV-1+ indicates HIV-1 infected individuals.  
HAART indicates a recipient of highly active anti-retroviral therapy.   
c  CD4 count indicates number of CD4+ T cells per ml of blood.   
d Viral load indicates number of HIV-1 viral genome per ml of serum sample.   
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Table 5. List of epitopes used for MHC class I tetramer production 
 
HLA alleles Epitope amino acid sequence Protein Epitope locationa 
A2 SLYNTVATL HIV-1 p17Gag 77-85 
A2 ILKEPVHGV HIV-1 Pol 309-317 
A2 GLCTLVAML EBV BMLF1 280-288 
A2 NLVPMVATV CMV pp65 493-503 
A3 RLRPGGKKK HIV-1 p17Gag 20-28 
A3 AIFQSSMTK HIV-1 Pol 158-166 
A3 QVPLRPMTYL HIV-1 Nef 73-82 
B8 EIYKRWII HIV-1 p24Gag 128-135 
B8 FLKEKGGL HIV-1 Nef 90-97 
B8 RAKFQLL EBV BZLF1 190-197 
 
a Epitope location is indicated by number of amino acids spanning the epitope from N-terminus of the 
corresponding protein.  
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Figure 9. (A) Visualization of virus-specific CD8+ T cells by staining ex vivo  with MHC class I 
tetramers and surface expression of memory/effector markers. (B) Surface expression of 
memory/effector phenotypic markers on virus-specific CD8+ T cells 
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Figure 10. (A) Comparison of percent CD27, CD28, CD57, and CD62L expressing EBV-, CMV-
, and HIV-1-specific CD8+ T cells. (B) EBV- and CMV-specific CD8+ T cells from HIV-1 
infected subjects displaying the pattern of marker expression similar to those CD8+ T cells from 
HIV-1 uninfected subjects.   
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Figure 11. (A) EBV (A)-specific CD8+ T cells from HIV-1 infected and uninfected subjects 
show similar proportions of CD27, CD28, CD57 and CD62L subsets. (B) CMV (B) -specific 
CD8+ T cells from HIV-1 infected and uninfected subjects show similar proportions of CD27, 
CD28, CD57 and CD62L subsets. (C) Comparison of proportions of CD27, CD28, CD57 and 
CD62L subsets of bulk CD8+ T cells expression (C) from HIV-1 infected (HIV-1+) and 
uninfected (HIV-1-) subjects
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Figure 12. A scatter matrix plot of each pairs of percent marker expression of EBV-, CMV-, and 
HIV-1-specific CD8+ T cells.  
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Figure 13. Correlation between the maker expression and frequency of EBV-, CMV-, HIV-
specific CD8+ T cells 
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Figure 14. (A) Comparison of percent CD27+CD57+, CD27+CD57–, CD27–CD57+, CD27–CD57–  
of EBV-, CMV-, and HIV-1-specific CD8+ T cells. (B) Representative three dimensional 
topographic plots of EBV-, CMV-, and HIV-1-specific CD8+ T cells. Color variation indicates a 
level of cell number from low (purple) to high (red).  A white arrow indicates a CD27–CD57high 
cluster. Representative subjects 1 and 2 are HIV-1 uninfected, while subjects 3, 4, and 5 are 
HIV-1 infected subjects.  Representative subject 4 is HIV infected, and  has EBV (BMLF1)-, 
CMV-, and HIV-1-specific CD8+ T cells. 
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Figure 15. A schematic diagram showing proposed CD8+ T cell functional subset enrichment of 
antigen-specific CD8+ T cells based on our 6-color study.  
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VI. 
DISCUSSION 
 
Phenotypic characterization of memory CD8+ T cells specific for FluA, EBV, CMV and HIV-1 
in post-primary infection revealed phenotypic enrichment of virus-specific CD8+ T cells 
according to each virus specificity.  The collective phenotypic enrichment of FluA-, EBV-, 
CMV- and HIV-1-specific CD8+ T cells were CD27+CD28+, CD27+CD28+, CD27–CD28–, 
CD27–CD28+ respectively (Figure. 5 and 15, and Table 2 and 3).  This is in agreement with the 
current model of virus-specific memory-effector CD8+ T cell differentiation originally proposed 
by Appay et. al. (22).  Thus, FluA- and EBV-specific CD8+ T cells are in the early/immature 
memory stage (CD27+CD28+), HIV-1-specific CD8+ T cells are in the intermediate memory 
stage (CD27+CD28–), and CMV-specific CD8+ T cells are in the effector/mature stage (CD27–
CD28–) of memory-effector differentiation.  
 In the first part of this dissertation, it was hypothesized that relatively unknown FluA-
specific CD8+ T cells considered to be the undifferentiated by the conventional definition 
(CD27+CD28+) (115) display the effector phenotype if characterized by a large number of 
phenotypic markers associated with the effector subset.  Although, results from the present study 
(based on analysis of 14 distinct phenotypic markers) clearly showed that FluA-specific CD8+ T 
cells were in a less differentiated memory stage than EBV-specific CD8+ T cells (Figure. 5), 
FluA-specific CD8+ T cells had similar degree of skewness toward effector cells as EBV-specific 
CD8+ T cells by their expression of effector markers (e.g. CCR5, CXCR3, granzyme A, CD94) 
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(Figure. 5).  Also, a similar proportion of FluA- and EBV-specific CD8+ T cells had immediate 
cytoplasmic IFN-γ production (Figure. 6B).  These results suggest that FluA-specific CD8+ T 
cells are as mature or differentiated memory cells as EBV-specific CD8+ T cells.  Thus, it 
appears that phenotypic assessment based on a lesser number of conventional maturation-
associated phenotypic markers (e.g. CD27 and CD28) does not accurately ascribe the memory-
effector differentiation of virus-specific CD8+ T cells.  
 Another important observation is that the proportion of CCR7-expressing FluA-specific 
CD8+ T cells was consistently lower than expected (Figure. 4 and 5, Table 2).  This observation 
was rather unusual, considering that the FluA-specific CD8+ T cell represents the 
immature/undifferentiated memory cell (24).  Accordingly, immature/undifferentiated memory 
cells should consist of a large number of TCM (CCR7+CD62L+).  There are two possible 
explanations for this contradictory observation: TCM cells lack virus-specific memory CD8+ T 
cells, or alternatively, in the absence of CCR7 expression, a CD62L+CCR7– subset becomes TCM.  
The latter appears to be the more likely, since the CD62L+ subset retains a capacity for lymph 
node homing, which is the most critical characteristic of TCM cells (139) by CXCR4 surface up-
regulation (induced by cross-linking of CD62L) (140).   
 Work done in the second part of this dissertation tested the hypothesis that CD62L+ virus-
specific central memory CD8+ T cells had a capacity of the immediate effector function.  
Specifically, experiments in this section addressed whether a CD62L+ subset of EBV-specific 
CD8+ T cells had potential for immediate cytoplasmic IFN-γ production, an one of critical 
immediate effector functions.  Results showed that CD62L+ CD8+ T cells specific for EBV 
antigen can produce cytoplasmic IFN-γ (Figure. 8A and B).  This suggests that CD62L and IFN-
γ are not confined to either TCM or TEM, but broadly expressed among various memory CD8+ T 
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cell subsets.  These observations are in accord with recent data that, in contrast to their CD4+ T 
cell counterparts, even naïve, cord blood-isolated CD8+ T cells are efficient producers of IFN-γ 
following short-term stimulation (132).  Markedly, there is a fraction of IFN-γ negative CD62L+ 
EBV-specific CD8+ T cells (Figure. 8A and B).  These cells may represent the classical TCM, if 
antigen-specific stimulation induces IL-2 production in these cells (131).   Further experiments 
are needed to confirm this.  
 A similar study showed that virus-specific CCR7+CD8+ T cells possess granzyme B, and 
produce IFN-γ upon peptide-specific stimulation (29).  The same authors concluded that CCR7 
expression on antigen-specific CD8+ T cells may not agree with the functional definition of TCM.  
Thus, antigen-specific IFN-γ response ex vivo  does not appear to distinguish effector memory 
(CCR7– and/or CD62L–) from central memory cells (CCR7+/–CD62L+).  It is increasingly clear 
that memory with respect to antigen-specificity is far more heterogeneous, and clear functional 
and phenotypic correlation will likely be difficult to establish.  Nonetheless, these considerations 
provide the rationale for further refinement of the functional and phenotypic definitions of virus-
specific CD8+ TCM and TEM. 
 In the  previous parts of this work, a high degree of heterogeneity was noted within virus-
specific CD8+ T cell memory population. This illustrates a markedly more complex stage of 
memory-effector differentiation of virus-specific memory CD8+ T cells than those defined to 
date using primarily phenotypic markers CD27 and CD28.  A larger combination of phenotypic 
markers is therefore necessary to ascertain more elaborate stages of memory-effector 
differentiation of virus CD8+ T cells.  Thus, experiments in specific aim 3 used 6-color flow 
cytometric analysis allowing the simultaneous detection of 4 distinct phenotypic markers (CD27, 
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CD28, CD57 and CD62L) on single virus-specific CD8+ T cells (Figure. 9B).  This permitted 
more accurate phenotypic assessment of virus-specific CD8+ T cells.   
 Accurate phenotypic assessment of virus-specific CD8+ T cells is critical for 
understanding significance of virus-specific CD8+ T cell memory-effector differentiation in 
controlling viral pathogenesis.  Of the several virus pathogenesis models in humans, HIV-1 
infection provides the best model system to study an interaction between virus-specific CD8+ T 
cells and virus pathogenesis.  Unlike EBV and CMV infection in asymptomatic virus carriers, 
HIV-1 infection is progressive, and onset and duration of infection and longitudinal clinical data 
(e.g. viral load) are typically available.  The caveat appears to be the significant clinical 
heterogeneity found among HIV-1 infected individuals.  This could potentially hinder the 
collective analysis of memory-effector differentiation of HIV-1-specific CD8+ T cells.   
 In the third part of this work, it was hypothesized that differentiation of HIV-1-specific 
CD8+ T cells from the intermediate to late/effector stage was impaired even though there is a 
continuous presence of HIV-1 antigens, which in theory should drive HIV-1-specific CD8+ T 
cells toward effector stage.  Previous reports showed phenotypic enrichment  of HIV-1-specific 
CD8+ T cells in the intermediate stage (CD27+CD28–) of CD8+ T cells differentiation regardless 
of clinical stages and duration of persistent HIV-1 infection (22, 84, 85, 141).  In agreement with 
these reports, 6-color phenotypic assessment in specific aim 3 showed the same overall 
phenotypic enrichment of HIV-1-specific CD8+ T cells based on the phenotypic markers used in 
this study (Figure. 15).  
 Notably, CD27 and CD57 expression of some EBV- and CMV-specific CD8+ T cells 
showed the peculiar pattern of progression from the most undifferentiated (CD27highCD57–) to 
the most differentiated stage (CD27–CD57high) (Figure. 14B). This strongly suggested that 
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memory-effector differentiation of HIV-1-specific CD8+ T cells might be impaired.  Although 
neither the conventional flow cytometric analysis (Figure. 14A) nor the conventional model 
(Figure. 15) did not show the exact nature of the differentiation impairment, the three 
dimensional topographical model (Figure. 14B) revealed that HIV-1-specific CD8+ T cells did 
not complete effector differentiation associated down-regulation of CD27 while these cells can 
nearly complete up-regulation of CD57.  Moreover, Global immune dysfunction due to 
progressive HIV-1 infection did not appear to be a cause of this since phenotypic enrichment of 
CMV-specific CD8+ T cells from HIV-1 infected subjects were not affected (Figure. 11B). 
 Alternatively, the differentiation impairment might be a result of deletion of the effector 
subset (CD27–CD57high) of the HIV-1-specific CD8+ T cell over the course of progressive HIV 
infection.  Deletion of the effector subset can be caused  by apoptosis, since CD57+CD8+ T cells 
are particularly prone to activation induced apoptosis (88), and Fas-mediated apoptosis(87).  
Interestingly, Fas-mediated apoptosis of the effector subset can be minimized by addition of IL-
15 (142), indicating that cytokine environment clearly influences a fate of the effector subset.  
Also, it is not clear as to how deletion of the effector subset occurs specifically for HIV-1-
specific CD8+ T cells (and not for CMV-specific CD8+ T cells).  These issues must be addressed 
further to determine how the effector subset of HIV-1-specific CD8+ T cells might be selectively 
deleted by activation-induced apoptosis.    
 In conclusion, the present study characterized phenotype and function of virus-specific 
CD8+ T cells in humans with three specific aims that focused on memory-effector differentiation 
of virus-specific CD8+ T cells.  The present study found that memory-effector differentiation of 
virus-specific CD8+ T cell deviated from the currently accepted model when a larger number of 
phenotypic markers were examined.  To refine the memory-effector CD8+ T cell differentiation, 
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a 6-color flow cytometric analysis was employed, and revealed finer stages of memory-effector 
differentiation (Figureure 17).  Furthermore, the 6-color flow cytometric analysis was used for 
phenotypic assessment of HIV-1-specific CD8+ T cells to ascertain viral modulation of memory-
effector CD8+ T cell differentiation.  Refined analysis revealed an impaired memory-effector 
differentiation of HIV-1-specific CD8+ T cell based on CD27 and CD57 expression.  Further 
study is needed to delineate the molecular defects causing the impairment in memory-effector 
differentiation of HIV-1-specific CD8+ T cells.   
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VII. 
FUTURE DIRECTIONS 
 
Phenotypic assessment of virus-specific CD8+ T cells will undoubtedly continue to progress with 
even more able technologies.  The most advanced flow cytometer currently available allows 
simultaneous analysis of up to 15 distinct markers on single cells (14).  When this type of flow 
cytometry becomes widely available, it will be possible to assess exceedingly detailed memory-
effector differentiation of virus-specific CD8+ T cells, given that a larger number of MHC class I 
tetrameric reagents become available.  A comprehensive list of virus-specific CD8+ T cell 
phenotypes clearly helps refine the model of memory-effector differentiation of virus-specific 
CD8+ T cells.   
 Equally important is the functional assessment of virus-specific CD8+ T cells.  The 
current functional assessment is far more limited than phenotypic assessment in defining stages 
of memory-effector virus-specific CD8+ T cells.   This will soon change since modern functional 
assays combined with the MHC class I tetrameric reagents have been developed to characterize 
various functions of virus-specific CD8+ T cells by flow cytometry (3).   
 Elucidation of memory-effector differentiation of virus-specific CD8+ T cells not only 
has enormous impact on advancement of modern immunology but also has significant public 
health implications.  Understanding the impairment of memory-effector differentiation of HIV-1-
specific CD8+ T cells, for instance, will greatly facilitate a design of effective vaccine against 
progressive HIV-1 infection.  Beyond HIV-1 vaccine development, knowledge from this type of 
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research is applicable for designing effective vaccines against practically any infectious diseases 
and also for effective treatment of neoplastic diseases. 
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APPENDIX A.  
 
 
 
 
Modified MHC Class Monomer and Oligomer Synthesis Protocol 
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INTRODUCTION 
 
A conventional method for producing MHC class I tetramers requires a large scale prokaryotic 
protein synthesis and complicated procedures that typically span over a week.  Before MHC 
class tetramers became freely available to NIH grant recipients about 5 years ago, this laboratory 
had to develop a more simplified “in house” procedure for obtaining recombinant MHC-peptide 
monomers and oligomers for completion of this Ph.D. dissertation project.  The modified method 
consisted of incorporation of an unpaired cysteine residue at the C-terminus of the HLA-A*2011 
heavy chain, allowing site-specific biotinylation by a SH-specific biotinylating reagent.  This 
significantly shortens the production time of MHC class I monomers and oligomers (including 
tetramers) .   
 Another advantage is that the modified method generates highly flexible MHC class I 
oligomers for a variety of different applications.  The recombinant MHC-peptide containing free 
sulfhydryls can be coupled to any solid surface (e.g. tissue culture plates, BIACORE chip™, 
glass/plastic array slides, microspheres, and Qdots™) that contains avidin or sulfhydryl reactive 
reagents. The sulfhydryl-specific coupling reagents allow conjugation of free sulfhydryl 
containing molecules to almost any solid surface.  These oligomers can be used to generate a 
superior antigen-specific staining reagent, an artificial antigen presenting particle and a T cell 
microarray for a variety of CD8+ T cells studies and therapy.   Thus, the modified method 
provides a simple, efficient and inexpensive procedure for making recombinant MHC class I - 
peptide oligomers, a highly specific and very useful reagent with a number of important 
applications in basic and clinical T cell research.  
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INCLUSION BODY PREPARATION AND PURIFICATION 
Materials 
• 1M MES  (0.195g in 1ml dH2O) 
• 2M DTT (0.3085g in 1ml dH2O) 
• Cell Lytic BII (Sigma) +10mM DTT 
o Prepare 100ml of 5ml CLBII + 95ml of dH2O+ 50ul of 2M DTT. 
• Washing Buffer – 500ml 
o 50mM Tris (pH 8.0) – 25ml 1M Tris (pH 8.0) 
o 100mM NaCl            — 50ml 1M NaCl 
o 1mM NaEDTA         — 1ml 0.5M NaEDTA 
o 1mM DTT                —  250ul 2M DTT 
• Washing Buffer with 0.5% Trition 
o 350ml of Washing Buffer + 1.75ml of Trition 
• Lysozyme (10mg/ml) 1ul of Ready-Lyse Lysozyme (Epicenter) 
• SS-34 rotor 
• Teflon coated Spatula (autoclaved) 
• Sonicator 
• Dunce Homegenizer (7ml or bigger) Autoclaved 
• LB Medium (prepare and autoclaved a day before) 
• IPTG (a stock is 0.5M) 
• Tubes 
o 15 and 50 mL Falcon tubes 
o 50ml Oakridge tubes (autoclaved) 
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• Antibiotics 
o Kanamysin —30ug/ml  (stock 10mg/ml) 
o Carbenicillin – 100ug/ml (50-100mg/ml) 
o Chroloamphinicol – 34ug/ml (34mg/ml) 
Method 
• Prepare and autoclave 1L LB medium in a 4L flask and store in a cold room. 
• Inoculate a colony in 3ml of LB (for A2CP Kanamysin (30ug/ml final) / for b2M 
Carbenecillin (100ug/ml final) + Chroloamphinicol (34ug/ml final).  
• Incubate overnight. 
• Warm 1L LB to room temp., and add 1-1.5ml of overnight culture. 
• Incubate 1L culture with rigorous shaking.  
• When O.D600 reaches 0.6-0.8 (it usually takes 2-2.5hrs), add 2ml of 0.5M IPTG (1mM 
final). 
• Continue incubate for another 4hrs. 
• Take a 1ml sample and run SDS-PAGE gen to see levels of induction (Figure 16).  
• Transfer 500ml of the culture to 4x 750ml centrifuge tube, and spin down bacteria at 4Co 
3000rpm (don’t want a hard pellet !!) for 30min.  
• Discard LB and drain a last bit of LB by placing the tube upside down a paper towel (do 
not disturb the pellet). 
• Store the pellet in –80Co freezer for overnight or longer if you wish. 
• Prepare all the buffers, and place them on ice. 
• Brake the pellet by tapping bottom of the tube (careful not to smash the tube.  The whole 
pellet should come off the bottom.), and catch pellet in a 50ml Falcon tube.  
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• Wash our remaining pellet with 5ml of Cell Lytic 10mM DTT. 
• Start sonication, when pellet is somewhat dissolve or settle at bottom.  
• Place the tube on an ice 
• Place a tip of a probe near bottom.  
• 20-pules at output 4, followed by 20-pulses at output 5 (take 10-30 sec break and mix in 
between each pulses).  Repeat this 10 times.   
• At the end of sonication, the solution should pore like water.  If not, continue to sonicate 
more. 
• Add 1ul of Ready-Lyse Lysozyme, and incubate for 10min at room temp. 
• Add 1/20 diluted Cell Lytic with 10mM DTT to 50ml, and transfer to 50ml Oakridge 
tube.  
• Spin the inclusion body down for 15min at 15000 rpm.  
• (From now on, everything must be done on ice !!) 
• Discard the liquid, and take pellet out of the tube with a spatula and into a homogenizer. 
• Add about 7ml or less of the Washing Buffer with 0.5% triton to the homogenizer. 
• Insert a piston and start homogenizing. 
• Transfer the liquid to an new 50ml Oakridge tube, and fill the tube with the same buffer. 
• Spin 15000rpm for 15min. 
• Repeat this washing step 3 times, and a last wash is done in the buffer w/o Triton. 
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Figure 16. SDS-PAGE of three proteins after 4hr induction in 1L culture.  Typically, BL21(DE3) 
bacteria produce up to 60% of total protein in the inclusion body when induced.  Smaller protein 
such as b2m is produced more than bigger proteins.   
 
Inclusion Body Denaturation 
Materials 
• Denaturant Solution (make 20ml) 
o 8M Urea (9.608g) 
o 25mM MES (250ul of 1M MES) 
o 10mM NaEDTA (400ul of 0.5M NaEDTA (8.0)) 
o 0.1mM (1ul of 2M DTT) 
Method 
• After the last wash w/o Triton, the inclusion body should look pale white pellet. 
• Transfer the inclusion body pellet to 15ml Falcon tube. 
• Add a denaturant solution (about 5ml for A2CP or 10ml for b2M) and incubate in the 
cold room for overnight on a rotator. 
• Spin junks down at 45000rpm for 20min 20Co 
A2BSP A2CP β2m 
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• Carefully take the denaturant out and make 0.5 ml aliquots in 1.5ml Eppendorf tubes.  
• Take small sample and measure protein concentration by BCA (use 1ul), and also run 
SDS-PAGE (need only 1-5ul).  Expected protein concentration is around 15-20mg/ml for 
A2Cp and twice as much for b2M (Figure 17).  
• Store them in –80 freezer.  
 
 
 
 
 
 
 
Figure 17. SDS-PAGE analysis of inclusion bodies dissolved in 8M Urea solution for overnight.  
5ul of dissolved inclusion bodies are loaded.  Typically, over 98% of inclusion bodies contain 
expressed A2CP or b2m protein.   
 
HLA REFOLDING 
Materials 
• Refolding Buffer (250ml) (pH 8.0-8.3) : RB 
• w/o Glutathione can be stored at 4CO 
o 100mM Tris-HCl (25ml of 1M Tris-HCl (pH8.0) 
o 400mM L-Arginine HCl (21g) 
o 2mM NaEDTA (1ml of 0.5M stock) 
o 0.5mM Oxid. Glutathione (76.5mg) 
o 5mM Redu. Glutathione (3.7g) 
β2M(50mg/ml) 
A2CP(25mg/ml) 
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• 3M Guanidine Solution pH 4.2 (100ml) Store at 4CO 
o 3M Guanidine-HCl (28.7g) 
o 10mM NaOAC (82mg) 
o 10mM NaEDTA (2ml of 0.5M stock) 
• Protease Inhibitor Cocktail (Calbiochem PI set III) 
o 1000 fold dilution (200uL) 
• Heavy Chain – 18.6mg total (3X6.2mg) 1uM final conc. 
• β2m – 13.2mg total (3x4.4mg) 2uM final conc. 
• Peptide – 12mg dissolve in 100 uL of DMSO 30uM final conc. (upto 100uM best for 
some peptides) 
• Two 27 gauge needles and 1ml syringes 
Methods 
(Preparation of Refolding Buffer in the morning or a day before to accommodate the first 8hr 
incubation.) 
• To 100ml of dH2O in a 250ml bottle, add Tris-HCl, L-arginine, and EDTA, bring a 
volume to 240ml. 
• Add oxidated and reduced glutathione (do not add glutathione if leaving RB overnight in 
the cold room).  
• Add a protease inhibitor cocktail 
• Check pH, and if necessary, adjust pH to 8.0. 
• Bring the volume to 250ml. 
• Cool RB to 10Co in ice.  
• Dissolve the peptide in 100ul DMSO 
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• Inject peptide with vigorous stirring. 
Preparation of Guanidine Solution.  
• In 250ml beaker, add 28.7 g of Guanindine and add dH2O to 50ml. 
• After dissolving Guanidine, add NaOAC and NaEDTA.  
• Bring the volume to 95ml, and adjust pH to 4.2, and then adjust the volume to 100ml 
• Store GS at 4CO but keep it at RT before the injection.  
Heavy chain and β2m injection. 
• Aliquot appropriate amount of HC and b2m in three 1.5ml eppendorf tubes.  Store them 
at –20Co till use.  
• Add 500ul of GS into thawed HC and b2m in the eppendorf tubes, vortex and quick spin.  
• Stir vigorously. 
• Using 27G 1ml syringe, forcefully inject b2m-GS right into the vortex.  Slow injection 
will result in the precipitation.  One should be able to see a huge plume coming out a tip 
of the needle.  
• Wait 1-5 min, and proceed with the second injection with HC-GS 
• Reduce stirring velocity, and incubate for 8hrs till the second injection (Do the first 
injection around noon, and second injection at 8pm). 
• Third injection will be 6-14hrs after the second injection (around 10am next morning).  
• Incubate additional 24-48 hrs.  (constantly monitoring the temp. ) 
 
CONCENTRATION OF THE REFOLDED HLA COMPLEX 
Materials 
• Amicon Stirred Concentrator (a model 8200, max capacity 200ml) 
• YM10 membrane 
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• 15ml Ultrafree Concentrator (Biomax 10) 
• 500ml beaker 
• 10ml pipet and removable pipeter 
Methods (in the cold room) 
• Cool Sorval RC-5C to 4Co. 
• Spin down RB in 4x 50ml polyproprene tubes (for a SS-34 rotor) at 15000rpm for 10min.  
• Carefully collect RB into a 250ml glass flask.  
• Assemble the stirred cell , and make sure everything is tight and secure.  
• Before applying the pressure, maker sure a regulator is set to less than 55psi.  
• Add 20ml of dH2O, assemble the rest of the stirred cell, and set the stirred cell on the top 
of the stirrers.  Start stirring. 
• Open a main valve of compressed N2 tank, and increase pressure to 55psi with a 
regulator.  
• Wash the membrane for 5min (for the brand new membrane) MilliQ water, or longer for 
the stored membrane (do not go down 5ml).  
• Close the valve, and discard the remaining water with a 10ml pipet.  
• Spin RB 15000rpm for 15min if there is a precipitate, otherwise it will clog membrane.  
• Place RB in the stirred cell.  Put a cap on (make sure tight and secure), and start stirring.  
• Open the valve, and make sure pressure stays 55psi during incubation.  
• Concentrate 200ml RB to around 10ml.  Normally, it would take 2hrs with 55psi.  
• Option:  Exchange buffer with PBS by adding 10ml of PBS at the time.  Don’t forget to add 
protease inhibitor cocktail !! 
• Cool Centrifuge to 4Co. 
• Load 4ml of RB into 4ml Ultrafree in 15 ml polyproprene Faclon tubes.  
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• Spin at 6000g (roughly 6000rpm on Sorval RT) at 4Co. (can go up to 7500g). 
• Further concentrate RB to 2ml.  It would roughly take 1-2hrs.  
 
PURIFICATION OF HLA MONOMERS BY FPLC 
Materials 
• FPLC Buffer (for BSP) pH 8.0 
o 20mM Tris-HCl 
o 50mM NaCl 
• FPLC Buffer (for A2CP) PBS pH 7.0 
Methods 
• Filter RB with 0.2um filter before loading.  
• A sample loop is 1ml so you need to run twice.  
• Collect fractions that correspond to A2 monomer.  Usually 3-5ml (Figure 18) 
• Concentrate A2 monomers to around 0.5-1ml 
• Measure concentration by BCA, and adjust it to 1-2mg/ml 
• Add protease inhibitor cocktail (1000x). 
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Figure 18. FPLC gel filtration profile shows multiple peaks of the concentrated refolding 
mixture.  A middle peak corresponds to the refolded recombinant HLA-A2 molecule with C-
terminus sulfhydryl group (SH).  Commassie stain of a SDS-PAGE gel from the fraction taken 
from each peaks shows that only the middle peak contains both recombinant HLA-A2 heavy 
chain and b2m. 
 
BIOTINYLATION OF HLA MONOMERS 
Materials 
• DTT – 1M Stock (154mg in 1ml MQ) – final conc. is 5mM 
• Class I monomer 
• PEO-Maleimide activated Biotin 
• PBST—PBS (7.0) + 5mM EDTA 
• 0.5M NaEDTA 
A2 aggregates Refolded  
A2 monomer 
β2M 
Peptide 
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• Protease Inhibitor Cocktail  
Methods 
• Add 5ul of 0.5M NaEDTA to 500ul RB (roughly contains 0.5-1mg of the monomer.) 
• Add 2.5ul of 1MDTT (final is 5mM) to 500ul of the monomer solution 
• Incubate 90min room temp (use a heat block). 
• Bring a volume to 2.5ml with PBST. 
• Get rid of DTT by running PD-10 desalting column. 
• Concentrate the monomer by 4ml Ultrafree down to 500ul (takes 5min). 
• Add PEO-maliemide-biotin (5 fold molar excess, and make fresh) 
• Incubate overnight.  
• Get rid of free biotin by FPLC. 
• Perform biotinylation test. 
o Add an 10fold excess FITC-SA, and incubate about an hour. 
o Add an 10fold excess biotinylated A2 monomer to FITC-SA and incubate an 
hour. 
o Run SDS-PAGE. (Figure 19)  
• Concentrate the monomer to 2mg/ml, and add the protease inhibitor cocktail. 
• Aliquot the monomer into 200ug/ml , snap freeze, and store them at –80. 
General Comment 
Unlike the BSP construct, A2CP can be chemically conjugated with variety of sulfhydryl (SH) 
reactive molecules (e.g. maleimide) that are currently available.  At certain pH, these thiol 
reactive molecules are very specific to thiol group, and reaction is completed in a matter of 
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hours.  Cochran et.al. took this advantage to produce a class II multimers.  This is a cheaper and 
easier alternative to biotinylation to BSP.   
 Cochran et.al. reported that a SH group at a carboxyl terminus is capped with glutathione 
during refolding.  This is why 5mM DTT is used to liberate -SH group.  Apparently, Class II 
proteins can tolerate 5mM DTT though Class I may not.  Perhaps, smaller amount may be 
sufficient since 1mM DTT (60min 37oC) can break SS bond between two heavy chains of IgG.   
 A     B 
 
 
 
 
Figure 19. (A) The recombinant A2CP without a biotin-tag does not bind streptavidin.  If binding 
occurs, A2CP band in the presence of SA (+SA) will shift to the arrow indicated by SA. (B) The 
recombinant A2CP (but not b2m) with a biotin-tag bind streptavidin. A2CP band only in the 
presence of SA (+SA) lane shifted to the arrow indicated by SA, whereas B2m band remained at 
the same size. Notice that A2CP band in SA+ lane is almost completely gone, suggesting, 
biotinylation proceeded nearly 100% efficiency and specificity. 
 
OLIGOMERZIATION OF HLA MONOMERS 
Materials 
• Streptavidin (non-Carbohydrate versions can also be used but staining may be less 
intense) 
• Conjugated with any fluorochromes (unlike an NIAID’s BSP based monomer), and 
also HRP or AP for a tissue staining and signal amplification (i.e. by TSA). 
 
A2CP 
SA 
β2M 
+SA -SA 
A2CP 
SA 
β2M 
+SA -SA 
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Methods 
• Calculate molar concentration of SA conjugated with a particular flourochorme (see 
NIAID’s protocol) 
• Add 1/10 of SA-flourchrome at time to the 200ug/ml monomer aliquot, and incubate 
30min. 
• Do this until all the SA is added. 
General Comment 
This procedure produces mixture of monomer-, dimmer-, trimer-, and tetramer-SA.  SA-PE is 
known to form oligomers which give stronger signal than other SA-florescent dye conjugates.  If 
the tetrameric form is needed, it is necessary to purify it only from a teterameric peak by FPLC.  
Technically, this procedure requires a bigger column (i.e. 2x HR10/30 with superdex 200, or 
HR16/30 HighLoad™ column), and a downside of using the bigger columns is that it takes a 
long time, and may lose substantial amount of tetramers.  One could also run a small sample on 
SDS-PAGE or FPLC (use a smaller sample loop (e.g. 50-100 ul)) to determine a degree of 
tetramerization.  For flow cytometry purpose, these steps are not necessary, and in fact, NIAID 
Tetramer Synthesis Facility does not further purify the tetrameric form, however other groups do 
purify the tetrameric form for flow cytometry.   
 
SELECTED READINGS 
Altman, J. D., P. A. Moss, P. J. Goulder, D. H. Barouch, M. G. McHeyzer-Williams, J. I. Bell, 
A. J. McMichael, and M. M. Davis. 1996. Phenotypic analysis of antigen-specific T 
lymphocytes. Science 274:94. 
 
Busch, D. H., and E. G. Pamer. 1998. MHC class I/peptide stability: implications for 
immunodominance, in vitro proliferation, and diversity of responding CTL. J Immunol 
160:4441. 
 
 106 
Busch, D. H., I. Pilip, and E. G. Pamer. 1998. Evolution of a complex T cell receptor repertoire 
during primary and recall bacterial infection. J Exp Med 188:61. 
 
Busch, D. H., I. M. Pilip, S. Vijh, and E. G. Pamer. 1998. Coordinate regulation of complex T 
cell populations responding to bacterial infection.Immunity 8:353. 
 
Cameron, T. O., J. R. Cochran, B. Yassine-Diab, R. P. Sekaly, and L. J. Stern. 2001. Cutting 
edge: detection of antigen-specific CD4+ T cells by HLA-DR1 oligomers is dependent on 
the T cell activation state. J Immunol 166:741. 
 
Cochran, J. R., T. O. Cameron, and L. J. Stern. 2000. The relationship of MHC-peptide binding 
and T cell activation probed using chemically defined MHC class II oligomers. Immunity 
12:241. 
 
Cochran, J. R., T. O. Cameron, J. D. Stone, J. B. Lubetsky, and L. J. Stern. 2001. Receptor 
proximity, not intermolecular orientation, is critical for triggering T-cell activation. J Biol 
Chem 276:28068. 
 
Cochran, J. R., and L. J. Stern. 2000. A diverse set of oligomeric class II MHC-peptide 
complexes for probing T-cell receptor interactions. Chem Biol 7:683. 
 
Garboczi, D. N., P. Ghosh, U. Utz, Q. R. Fan, W. E. Biddison, and D. C. Wiley. 1996. Structure 
of the complex between human T-cell receptor, viral peptide and HLA-A2. Nature 
384:134. 
 
Garboczi, D. N., U. Utz, P. Ghosh, A. Seth, J. Kim, E. A. VanTienhoven, W. E. Biddison, and D. 
C. Wiley. 1996. Assembly, specific binding, and crystallization of a human TCR-
alphabeta with an antigenic Tax peptide from human T lymphotropic virus type 1 and the 
class I MHC molecule HLA-A2. J Immunol 157:5403. 
 107 
 
 
 
 
BIBLIOGRAPHY 
 
 
 
1. Wherry EJ, Teichgraber V, Becker TC, Masopust D, Kaech SM, Antia R, von 
Andrian UH, Ahmed R. 2003. Lineage relationship and protective immunity of 
memory CD8 T cell subsets. Nat Immunol 4: 225-34 
 
2. Altman JD, Moss PA, Goulder PJ, Barouch DH, McHeyzer-Williams MG, Bell JI, 
McMichael AJ, Davis MM. 1996. Phenotypic analysis of antigen-specific T 
lymphocytes. Science 274: 94-6 
 
3. Appay V, Rowland-Jones SL. 2002. The assessment of antigen-specific CD8+ T cells 
through the combination of MHC class I tetramer and intracellular staining. J 
Immunol Methods 268: 9-19 
 
4. Xu XN, Screaton GR. 2002. MHC/peptide tetramer-based studies of T cell function. 
J Immunol Methods 268: 21-8 
 
5. McMichael AJ, Rowland-Jones SL. 2001. Cellular immune responses to HIV. 
Nature 410: 980-7. 
 
6. Picker LJ, Treer JR, Ferguson-Darnell B, Collins PA, Buck D, Terstappen LW. 
1993. Control of lymphocyte recirculation in man. I. Differential regulation of the 
peripheral lymph node homing receptor L-selection on T cells during the virgin to 
memory cell transition. J Immunol 150: 1105-21. 
 
7. Tedder TF, Steeber DA, Pizcueta P. 1995. L-selectin-deficient mice have impaired 
leukocyte recruitment into inflammatory sites. J Exp Med 181: 2259-64. 
 
8. Cyster JG. 2000. Leukocyte migration: scent of the T zone. Curr Biol 10: R30-3. 
 
9. Gamadia LE, van Leeuwen EM, Remmerswaal EB, Yong SL, Surachno S, 
Wertheim-van Dillen PM, Ten Berge IJ, Van Lier RA. 2004. The size and phenotype 
of virus-specific T cell populations is determined by repetitive antigenic stimulation 
and environmental cytokines. J Immunol 172: 6107-14. 
 
10. Azuma M, Phillips JH, Lanier LL. 1993. CD28- T lymphocytes. Antigenic and 
functional properties. J Immunol 150: 1147-59. 
 
11. Cebo C, Dambrouck T, Maes E, Laden C, Strecker G, Michalski JC, Zanetta JP. 
2001. Recombinant human interleukins IL-1alpha, IL-1beta, IL-4, IL-6, and IL-7 
 108 
show different and specific calcium-independent carbohydrate-binding properties. J 
Biol Chem 276: 5685-91. 
 
12. Cebo C, Durier V, Lagant P, Maes E, Florea D, Lefebvre T, Strecker G, Vergoten 
G, Zanetta JP. 2002. Function and molecular modeling of the interaction between 
human interleukin 6 and its HNK-1 oligosaccharide ligands. J Biol Chem 277: 
12246-52. 
 
13. Vargas AL, Lechner F, Kantzanou M, Phillips RE, Klenerman P. 2001. Ex vivo 
analysis of phenotype and TCR usage in relation to CD45 isoform expression on 
cytomegalovirus-specific CD8+ T lymphocytes. Clin Exp Immunol 125: 432-9. 
 
14. De Rosa SC, Herzenberg LA, Roederer M. 2001. 11-color, 13-parameter flow 
cytometry: Identification of human naive T cells by phenotype, function, and T-cell 
receptor diversity. Nat Med 7: 245-8. 
 
15. Merkenschlager M, Beverley PC. 1989. Evidence for differential expression of CD45 
isoforms by precursors for memory-dependent and independent cytotoxic 
responses: human CD8 memory CTLp selectively express CD45RO (UCHL1). Int 
Immunol 1: 450-9. 
 
16. Roederer M, Dubs JG, Anderson MT, Raju PA, Herzenberg LA. 1995. CD8 naive T 
cell counts decrease progressively in HIV-infected adults. J Clin Invest 95: 2061-6. 
 
17. Hintzen RQ, de Jong R, Lens SM, Brouwer M, Baars P, van Lier RA. 1993. 
Regulation of CD27 expression on subsets of mature T-lymphocytes. J Immunol 151: 
2426-35. 
 
18. Okumura M, Fujii Y, Inada K, Nakahara K, Matsuda H. 1993. Both CD45RA+ and 
CD45RA- subpopulations of CD8+ T cells contain cells with high levels of 
lymphocyte function-associated antigen-1 expression, a phenotype of primed T cells. 
J Immunol 150: 429-37. 
 
19. Hamann D, Baars PA, Rep MH, Hooibrink B, Kerkhof-Garde SR, Klein MR, van 
Lier RA. 1997. Phenotypic and functional separation of memory and effector 
human CD8+ T cells. J Exp Med 186: 1407-18. 
 
20. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. 1999. Two subsets of 
memory T lymphocytes with distinct homing potentials and effector functions. 
Nature 401: 708-12. 
 
21. Geginat J, Sallusto F, Lanzavecchia A. 2003. Cytokine-driven proliferation and 
differentiation of human naive, central memory and effector memory CD4+ T cells. 
Pathol Biol (Paris) 51: 64-6. 
 
 109 
22. Appay V, Dunbar PR, Callan M, Klenerman P, Gillespie GM, Papagno L, Ogg GS, 
King A, Lechner F, Spina CA, Little S, Havlir DV, Richman DD, Gruener N, Pape 
G, Waters A, Easterbrook P, Salio M, Cerundolo V, McMichael AJ, Rowland-Jones 
SL. 2002. Memory CD8+ T cells vary in differentiation phenotype in different 
persistent virus infections. Nat Med 8: 379-85. 
 
23. Appay V, Rowland-Jones SL. 2002. Premature ageing of the immune system: the 
cause of AIDS? Trends Immunol 23: 580-5. 
 
24. van Lier RA, ten Berge IJ, Gamadia LE. 2003. Human CD8(+) T-cell differentiation 
in response to viruses. Nat Rev Immunol 3: 931-9. 
 
25. Gamadia LE, Rentenaar RJ, Baars PA, Remmerswaal EB, Weel JF, Surachno S, 
Toebes M, Schumacher TN, ten Berge IJ, van Lier RAW. 2001. the differentiation 
of cytomegalovirusspecific CD8 positive T cells in healthy and immunosuppressed 
virus carriers. Blood 98: 754-61. 
 
26. Ahmed R, Gray D. 1996. Immunological memory and protective immunity: 
understanding their relation. Science 272: 54-60. 
 
27. Zinkernagel RM. 2000. What is missing in immunology to understand immunity? 
Nat Immunol 1: 181-5. 
 
28. Wherry EJ, Blattman JN, Murali-Krishna K, van der Most R, Ahmed R. 2003. 
Viral persistence alters CD8 T-cell immunodominance and tissue distribution and 
results in distinct stages of functional impairment. J Virol 77: 4911-27. 
 
29. Ravkov EV, Myrick CM, Altman JD. 2003. Immediate early effector functions of 
virus-specific CD8+CCR7+ memory cells in humans defined by HLA and CC 
chemokine ligand 19 tetramers. J Immunol 170: 2461-8. 
 
30. Zajac AJ, Blattman JN, Murali-Krishna K, Sourdive DJ, Suresh M, Altman JD, 
Ahmed R. 1998. Viral immune evasion due to persistence of activated T cells 
without effector function [see comments]. J Exp Med 188: 2205-13. 
 
31. Sun JC, Bevan MJ. 2003. Defective CD8 T cell memory following acute infection 
without CD4 T cell help. Science 300: 339-42. 
 
32. van Baarle D, Kostense S, van Oers MH, Hamann D, Miedema F. 2002. Failing 
immune control as a result of impaired CD8(+) T-cell maturation: CD27 might 
provide a clue. Trends Immunol 23: 586-91. 
 
33. Brodie SJ, Lewinsohn DA, Patterson BK, Jiyamapa D, Krieger J, Corey L, 
Greenberg PD, Riddell SR. 1999. In vivo migration and function of transferred 
HIV-1-specific cytotoxic T cells. Nat Med 5: 34-41. 
 
 110 
34. Dunbar PR, Smith CL, Chao D, Salio M, Shepherd D, Mirza F, Lipp M, 
Lanzavecchia A, Sallusto F, Evans A, Russell-Jones R, Harris AL, Cerundolo V. 
2000. A shift in the phenotype of melan-A-specific CTL identifies melanoma patients 
with an active tumor-specific immune response. J Immunol 165: 6644-52. 
 
35. Appay V, Nixon DF, Donahoe SM, Gillespie GM, Dong T, King A, Ogg GS, Spiegel 
HM, Conlon C, Spina CA, Havlir DV, Richman DD, Waters A, Easterbrook P, 
McMichael AJ, Rowland-Jones SL. 2000. HIV-specific CD8(+) T cells produce 
antiviral cytokines but are impaired in cytolytic function. J Exp Med 192: 63-75. 
 
36. Knowles DM. 1999. Immunodeficiency-associated lymphoproliferative disorders. 
Mod Pathol 12: 200-17. 
 
37. Herbst H. 1996. Epstein-Barr virus in Hodgkin's disease. Semin Cancer Biol 7: 183-
9. 
 
38. Henle W, Henle G, Lennette ET. 1979. The Epstein-Barr virus. Sci Am 241: 48-59. 
 
39. Niedobitek G, Agathanggelou A, Herbst H, Whitehead L, Wright DH, Young LS. 
1997. Epstein-Barr virus (EBV) infection in infectious mononucleosis: virus latency, 
replication and phenotype of EBV-infected cells. J Pathol 182: 151-9. 
 
40. Callan MF. 2004. The immune response to Epstein-Barr virus. Microbes Infect 6: 
937-45. 
 
41. Callan MF, Tan L, Annels N, Ogg GS, Wilson JD, O'Callaghan CA, Steven N, 
McMichael AJ, Rickinson AB. 1998. Direct visualization of antigen-specific CD8+ T 
cells during the primary immune response to Epstein-Barr virus In vivo. J Exp Med 
187: 1395-402. 
 
42. Steven NM, Leese AM, Annels NE, Lee SP, Rickinson AB. 1996. Epitope focusing in 
the primary cytotoxic T cell response to Epstein-Barr virus and its relationship to T 
cell memory. J Exp Med 184: 1801-13. 
 
43. Callan MF, Fazou C, Yang H, Rostron T, Poon K, Hatton C, McMichael AJ. 2000. 
CD8(+) T-cell selection, function, and death in the primary immune response in 
vivo. J Clin Invest 106: 1251-61. 
 
44. Silins SL, Cross SM, Elliott SL, Pye SJ, Burrows SR, Burrows JM, Moss DJ, Argaet 
VP, Misko IS. 1996. Development of Epstein-Barr virus-specific memory T cell 
receptor clonotypes in acute infectious mononucleosis. J Exp Med 184: 1815-24. 
 
45. Callan MF, Steven N, Krausa P, Wilson JD, Moss PA, Gillespie GM, Bell JI, 
Rickinson AB, McMichael AJ. 1996. Large clonal expansions of CD8+ T cells in 
acute infectious mononucleosis. Nat Med 2: 906-11. 
 
 111 
46. Tan LC, Gudgeon N, Annels NE, Hansasuta P, O'Callaghan CA, Rowland-Jones S, 
McMichael AJ, Rickinson AB, Callan MF. 1999. A re-evaluation of the frequency of 
CD8+ T cells specific for EBV in healthy virus carriers. J Immunol 162: 1827-35. 
 
47. Hislop AD, Annels NE, Gudgeon NH, Leese AM, Rickinson AB. 2002. Epitope-
specific evolution of human CD8(+) T cell responses from primary to persistent 
phases of Epstein-Barr virus infection. J Exp Med 195: 893-905. 
 
48. Blake N, Haigh T, Shaka'a G, Croom-Carter D, Rickinson A. 2000. The importance 
of exogenous antigen in priming the human CD8+ T cell response: lessons from the 
EBV nuclear antigen EBNA1. J Immunol 165: 7078-87. 
 
49. Revello MG, Gerna G. 2002. Diagnosis and management of human cytomegalovirus 
infection in the mother, fetus, and newborn infant. Clin Microbiol Rev 15: 680-715. 
 
50. Hummel M, Abecassis MM. 2002. A model for reactivation of CMV from latency. J 
Clin Virol 25 Suppl 2: S123-36. 
 
51. Scholz M, Doerr HW, Cinatl J. 2003. Human cytomegalovirus retinitis: 
pathogenicity, immune evasion and persistence. Trends Microbiol 11: 171-8. 
 
52. Elkington R, Walker S, Crough T, Menzies M, Tellam J, Bharadwaj M, Khanna R. 
2003. Ex vivo profiling of CD8+-T-cell responses to human cytomegalovirus reveals 
broad and multispecific reactivities in healthy virus carriers. J Virol 77: 5226-40. 
 
53. Kondo E, Akatsuka Y, Kuzushima K, Tsujimura K, Asakura S, Tajima K, Kagami 
Y, Kodera Y, Tanimoto M, Morishima Y, Takahashi T. 2004. Identification of novel 
CTL epitopes of CMV-pp65 presented by a variety of HLA alleles. Blood 103: 630-8. 
 
54. Gamadia LE, Remmerswaal EB, Weel JF, Bemelman F, van Lier RA, Ten Berge IJ. 
2003. Primary immune responses to human CMV: a critical role for IFN-gamma-
producing CD4+ T cells in protection against CMV disease. Blood 101: 2686-92. 
 
55. Komatsu H, Sierro S, A VC, Klenerman P. 2003. Population analysis of antiviral T 
cell responses using MHC class I-peptide tetramers. Clin Exp Immunol 134: 9-12. 
 
56. Khan N, Shariff N, Cobbold M, Bruton R, Ainsworth JA, Sinclair AJ, Nayak L, 
Moss PA. 2002. Cytomegalovirus seropositivity drives the CD8 T cell repertoire 
toward greater clonality in healthy elderly individuals. J Immunol 169: 1984-92. 
 
57. Weekes MP, Wills MR, Mynard K, Carmichael AJ, Sissons JG. 1999. The memory 
cytotoxic T-lymphocyte (CTL) response to human cytomegalovirus infection 
contains individual peptide-specific CTL clones that have undergone extensive 
expansion in vivo. J Virol 73: 2099-108. 
 
 112 
58. Peggs K, Verfuerth S, Pizzey A, Ainsworth J, Moss P, Mackinnon S. 2002. 
Characterization of human cytomegalovirus peptide-specific CD8(+) T-cell 
repertoire diversity following in vitro restimulation by antigen-pulsed dendritic 
cells. Blood 99: 213-23. 
 
59. Pantaleo G, Graziosi C, Butini L, Pizzo PA, Schnittman SM, Kotler DP, Fauci AS. 
1991. Lymphoid organs function as major reservoirs for human immunodeficiency 
virus. Proc Natl Acad Sci U S A 88: 9838-42. 
 
60. Coffin JM. 1995. HIV population dynamics in vivo: implications for genetic 
variation, pathogenesis, and therapy. Science 267: 483-9. 
 
61. Embretson J, Zupancic M, Ribas JL, Burke A, Racz P, Tenner-Racz K, Haase AT. 
1993. Massive covert infection of helper T lymphocytes and macrophages by HIV 
during the incubation period of AIDS. Nature 362: 359-62. 
 
62. Pantaleo G, Graziosi C, Demarest JF, Butini L, Montroni M, Fox CH, Orenstein 
JM, Kotler DP, Fauci AS. 1993. HIV infection is active and progressive in lymphoid 
tissue during the clinically latent stage of disease. Nature 362: 355-8. 
 
63. Mellors JW, Rinaldo CR, Jr., Gupta P, White RM, Todd JA, Kingsley LA. 1996. 
Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 
272: 1167-70. 
 
64. Koup RA, Safrit JT, Cao Y, Andrews CA, McLeod G, Borkowsky W, Farthing C, 
Ho DD. 1994. Temporal association of cellular immune responses with the initial 
control of viremia in primary human immunodeficiency virus type 1 syndrome. J 
Virol 68: 4650-5. 
 
65. Borrow P, Lewicki H, Hahn BH, Shaw GM, Oldstone MB. 1994. Virus-specific 
CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary 
human immunodeficiency virus type 1 infection. J Virol 68: 6103-10. 
 
66. Pantaleo G, Demarest JF, Soudeyns H, Graziosi C, Denis F, Adelsberger JW, 
Borrow P, Saag MS, Shaw GM, Sekaly RP, et al. 1994. Major expansion of CD8+ T 
cells with a predominant V beta usage during the primary immune response to HIV. 
Nature 370: 463-7. 
 
67. Musey L, Hughes J, Schacker T, Shea T, Corey L, McElrath MJ. 1997. Cytotoxic-T-
cell responses, viral load, and disease progression in early human immunodeficiency 
virus type 1 infection. N Engl J Med 337: 1267-74. 
 
68. Kaul R, Plummer FA, Kimani J, Dong T, Kiama P, Rostron T, Njagi E, MacDonald 
KS, Bwayo JJ, McMichael AJ, Rowland-Jones SL. 2000. HIV-1-specific mucosal 
CD8+ lymphocyte responses in the cervix of HIV-1-resistant prostitutes in Nairobi. 
J Immunol 164: 1602-11. 
 113 
69. Rowland-Jones S, Sutton J, Ariyoshi K, Dong T, Gotch F, McAdam S, Whitby D, 
Sabally S, Gallimore A, Corrah T, et al. 1995. HIV-specific cytotoxic T-cells in HIV-
exposed but uninfected Gambian women. Nat Med 1: 59-64. 
 
70. Goulder PJ, Phillips RE, Colbert RA, McAdam S, Ogg G, Nowak MA, Giangrande 
P, Luzzi G, Morgan B, Edwards A, McMichael AJ, Rowland-Jones S. 1997. Late 
escape from an immunodominant cytotoxic T-lymphocyte response associated with 
progression to AIDS. Nat Med 3: 212-7. 
 
71. Phillips RE, Rowland-Jones S, Nixon DF, Gotch FM, Edwards JP, Ogunlesi AO, 
Elvin JG, Rothbard JA, Bangham CR, Rizza CR, et al. 1991. Human 
immunodeficiency virus genetic variation that can escape cytotoxic T cell 
recognition. Nature 354: 453-9. 
 
72. Betts MR, Ambrozak DR, Douek DC, Bonhoeffer S, Brenchley JM, Casazza JP, 
Koup RA, Picker LJ. 2001. Analysis of total human immunodeficiency virus (HIV)-
specific CD4(+) and CD8(+) T-cell responses: relationship to viral load in untreated 
HIV infection. J Virol 75: 11983-91. 
 
73. Addo MM, Yu XG, Rathod A, Cohen D, Eldridge RL, Strick D, Johnston MN, 
Corcoran C, Wurcel AG, Fitzpatrick CA, Feeney ME, Rodriguez WR, Basgoz N, 
Draenert R, Stone DR, Brander C, Goulder PJ, Rosenberg ES, Altfeld M, Walker 
BD. 2003. Comprehensive epitope analysis of human immunodeficiency virus type 1 
(HIV-1)-specific T-cell responses directed against the entire expressed HIV-1 
genome demonstrate broadly directed responses, but no correlation to viral load. J 
Virol 77: 2081-92. 
 
74. Schmitz JE, Kuroda MJ, Santra S, Sasseville VG, Simon MA, Lifton MA, Racz P, 
Tenner-Racz K, Dalesandro M, Scallon BJ, Ghrayeb J, Forman MA, Montefiori 
DC, Rieber EP, Letvin NL, Reimann KA. 1999. Control of viremia in simian 
immunodeficiency virus infection by CD8+ lymphocytes. Science 283: 857-60. 
 
75. Jin X, Bauer DE, Tuttleton SE, Lewin S, Gettie A, Blanchard J, Irwin CE, Safrit JT, 
Mittler J, Weinberger L, Kostrikis LG, Zhang L, Perelson AS, Ho DD. 1999. 
Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian 
immunodeficiency virus-infected macaques. J Exp Med 189: 991-8. 
 
76. Yasutomi Y, Reimann KA, Lord CI, Miller MD, Letvin NL. 1993. Simian 
immunodeficiency virus-specific CD8+ lymphocyte response in acutely infected 
rhesus monkeys. J Virol 67: 1707-11. 
 
77. Chen ZW, Kou ZC, Lekutis C, Shen L, Zhou D, Halloran M, Li J, Sodroski J, Lee-
Parritz D, Letvin NL. 1995. T cell receptor V beta repertoire in an acute infection of 
rhesus monkeys with simian immunodeficiency viruses and a chimeric simian-
human immunodeficiency virus. J Exp Med 182: 21-31. 
 114 
78. Kuroda MJ, Schmitz JE, Charini WA, Nickerson CE, Lifton MA, Lord CI, Forman 
MA, Letvin NL. 1999. Emergence of CTL coincides with clearance of virus during 
primary simian immunodeficiency virus infection in rhesus monkeys. J Immunol 
162: 5127-33. 
 
79. Barouch DH, Santra S, Schmitz JE, Kuroda MJ, Fu TM, Wagner W, Bilska M, 
Craiu A, Zheng XX, Krivulka GR, Beaudry K, Lifton MA, Nickerson CE, Trigona 
WL, Punt K, Freed DC, Guan L, Dubey S, Casimiro D, Simon A, Davies ME, 
Chastain M, Strom TB, Gelman RS, Montefiori DC, Lewis MG, Emini EA, Shiver 
JW, Letvin NL. 2000. Control of viremia and prevention of clinical AIDS in rhesus 
monkeys by cytokine-augmented DNA vaccination. Science 290: 486-92. 
 
80. Seth A, Ourmanov I, Schmitz JE, Kuroda MJ, Lifton MA, Nickerson CE, Wyatt L, 
Carroll M, Moss B, Venzon D, Letvin NL, Hirsch VM. 2000. Immunization with a 
modified vaccinia virus expressing simian immunodeficiency virus (SIV) Gag-Pol 
primes for an anamnestic Gag-specific cytotoxic T-lymphocyte response and is 
associated with reduction of viremia after SIV challenge. J Virol 74: 2502-9. 
 
81. Amara RR, Villinger F, Altman JD, Lydy SL, O'Neil SP, Staprans SI, Montefiori 
DC, Xu Y, Herndon JG, Wyatt LS, Candido MA, Kozyr NL, Earl PL, Smith JM, 
Ma HL, Grimm BD, Hulsey ML, Miller J, McClure HM, McNicholl JM, Moss B, 
Robinson HL. 2001. Control of a mucosal challenge and prevention of AIDS by a 
multiprotein DNA/MVA vaccine. Science 292: 69-74. 
 
82. Shiver JW, Fu TM, Chen L, Casimiro DR, Davies ME, Evans RK, Zhang ZQ, 
Simon AJ, Trigona WL, Dubey SA, Huang L, Harris VA, Long RS, Liang X, Handt 
L, Schleif WA, Zhu L, Freed DC, Persaud NV, Guan L, Punt KS, Tang A, Chen M, 
Wilson KA, Collins KB, Heidecker GJ, Fernandez VR, Perry HC, Joyce JG, Grimm 
KM, Cook JC, Keller PM, Kresock DS, Mach H, Troutman RD, Isopi LA, Williams 
DM, Xu Z, Bohannon KE, Volkin DB, Montefiori DC, Miura A, Krivulka GR, 
Lifton MA, Kuroda MJ, Schmitz JE, Letvin NL, Caulfield MJ, Bett AJ, Youil R, 
Kaslow DC, Emini EA. 2002. Replication-incompetent adenoviral vaccine vector 
elicits effective anti-immunodeficiency-virus immunity. Nature 415: 331-5. 
 
83. Gulzar N, Copeland KF. 2004. CD8+ T-cells: function and response to HIV 
infection. Curr HIV Res 2: 23-37. 
 
84. Appay V, Papagno L, Spina CA, Hansasuta P, King A, Jones L, Ogg GS, Little S, 
McMichael AJ, Richman DD, Rowland-Jones SL. 2002. Dynamics of T cell 
responses in HIV infection. J Immunol 168: 3660-6. 
 
85. Papagno L, Appay V, Sutton J, Rostron T, Gillespie GM, Ogg GS, King A, 
Makadzanhge AT, Waters A, Balotta C, Vyakarnam A, Easterbrook PJ, Rowland-
Jones SL. 2002. Comparison between HIV- and CMV-specific T cell responses in 
long-term HIV infected donors. Clin Exp Immunol 130: 509-17. 
 
 115 
86. van Baarle D, Kostense S, Hovenkamp E, Ogg G, Nanlohy N, Callan MF, Dukers 
NH, McMichael AJ, van Oers MH, Miedema F. 2002. Lack of Epstein-Barr virus- 
and HIV-specific CD27- CD8+ T cells is associated with progression to viral disease 
in HIV-infection. Aids 16: 2001-11. 
 
87. Mueller YM, De Rosa SC, Hutton JA, Witek J, Roederer M, Altman JD, Katsikis 
PD. 2001. Increased CD95/Fas-induced apoptosis of HIV-specific CD8(+) T cells. 
Immunity 15: 871-82. 
 
88. Brenchley JM, Karandikar NJ, Betts MR, Ambrozak DR, Hill BJ, Crotty LE, 
Casazza JP, Kuruppu J, Migueles SA, Connors M, Roederer M, Douek DC, Koup 
RA. 2003. Expression of CD57 defines replicative senescence and antigen-induced 
apoptotic death of CD8+ T cells. Blood 101: 2711-20. 
 
89. Garba ML, Pilcher CD, Bingham AL, Eron J, Frelinger JA. 2002. HIV antigens can 
induce TGF-beta(1)-producing immunoregulatory CD8+ T cells. J Immunol 168: 
2247-54. 
 
90. Kostense S, Vandenberghe K, Joling J, Van Baarle D, Nanlohy N, Manting E, 
Miedema F. 2002. Persistent numbers of tetramer+ CD8(+) T cells, but loss of 
interferon-gamma+ HIV-specific T cells during progression to AIDS. Blood 99: 
2505-11. 
 
91. Trimble LA, Shankar P, Patterson M, Daily JP, Lieberman J. 2000. Human 
immunodeficiency virus-specific circulating CD8 T lymphocytes have down-
modulated CD3zeta and CD28, key signaling molecules for T-cell activation. J Virol 
74: 7320-30. 
 
92. Zhang D, Shankar P, Xu Z, Harnisch B, Chen G, Lange C, Lee SJ, Valdez H, 
Lederman MM, Lieberman J. 2003. Most antiviral CD8 T cells during chronic viral 
infection do not express high levels of perforin and are not directly cytotoxic. Blood 
101: 226-35. 
 
93. Migueles SA, Laborico AC, Shupert WL, Sabbaghian MS, Rabin R, Hallahan CW, 
Van Baarle D, Kostense S, Miedema F, McLaughlin M, Ehler L, Metcalf J, Liu S, 
Connors M. 2002. HIV-specific CD8+ T cell proliferation is coupled to perforin 
expression and is maintained in nonprogressors. Nat Immunol 3: 1061-8. 
 
94. Lichterfeld M, Kaufmann DE, Yu XG, Mui SK, Addo MM, Johnston MN, Cohen D, 
Robbins GK, Pae E, Alter G, Wurcel A, Stone D, Rosenberg ES, Walker BD, Altfeld 
M. 2004. Loss of HIV-1-specific CD8+ T cell proliferation after acute HIV-1 
infection and restoration by vaccine-induced HIV-1-specific CD4+ T cells. J Exp 
Med 200: 701-12. 
 
95. Kalams SA, Walker BD. 1998. The critical need for CD4 help in maintaining 
effective cytotoxic T lymphocyte responses. J Exp Med 188: 2199-204. 
 116 
96. Jiang H, Chess L. 2004. An integrated view of suppressor T cell subsets in 
immunoregulation. J Clin Invest 114: 1198-208. 
 
97. Kumar V. 2004. Homeostatic control of immunity by TCR peptide-specific Tregs. J 
Clin Invest 114: 1222-6. 
 
98. Aandahl EM, Michaelsson J, Moretto WJ, Hecht FM, Nixon DF. 2004. Human 
CD4+ CD25+ regulatory T cells control T-cell responses to human 
immunodeficiency virus and cytomegalovirus antigens. J Virol 78: 2454-9. 
 
99. Weiss L, Donkova-Petrini V, Caccavelli L, Balbo M, Carbonneil C, Levy Y. 2004. 
Human immunodeficiency virus-driven expansion of CD4+CD25+ regulatory T 
cells, which suppress HIV-specific CD4 T-cell responses in HIV-infected patients. 
Blood 104: 3249-56. 
 
100. Kinter AL, Hennessey M, Bell A, Kern S, Lin Y, Daucher M, Planta M, 
McGlaughlin M, Jackson R, Ziegler SF, Fauci AS. 2004. CD25(+)CD4(+) regulatory 
T cells from the peripheral blood of asymptomatic HIV-infected individuals regulate 
CD4(+) and CD8(+) HIV-specific T cell immune responses in vitro and are 
associated with favorable clinical markers of disease status. J Exp Med 200: 331-43. 
 
101. Deeks SG, Walker BD. 2004. The immune response to AIDS virus infection: good, 
bad, or both? J Clin Invest 113: 808-10. 
 
102. Zinkernagel RM. 2002. Immunity, immunopathology and vaccines against HIV? 
Vaccine 20: 1913-7. 
 
103. Broussard SR, Staprans SI, White R, Whitehead EM, Feinberg MB, Allan JS. 2001. 
Simian immunodeficiency virus replicates to high levels in naturally infected 
African green monkeys without inducing immunologic or neurologic disease. J Virol 
75: 2262-75. 
 
104. Peyerl FW, Barouch DH, Letvin NL. 2004. Structural constraints on viral escape 
from HIV- and SIV-specific cytotoxic T-lymphocytes. Viral Immunol 17: 144-51. 
 
105. Allen TM, O'Connor DH, Jing P, Dzuris JL, Mothe BR, Vogel TU, Dunphy E, Liebl 
ME, Emerson C, Wilson N, Kunstman KJ, Wang X, Allison DB, Hughes AL, 
Desrosiers RC, Altman JD, Wolinsky SM, Sette A, Watkins DI. 2000. Tat-specific 
cytotoxic T lymphocytes select for SIV escape variants during resolution of primary 
viraemia. Nature 407: 386-90. 
 
106. Levy JA. 2003. The search for the CD8+ cell anti-HIV factor (CAF). Trends 
Immunol 24: 628-32. 
 
107. Blackbourn DJ, Mackewicz CE, Barker E, Hunt TK, Herndier B, Haase AT, Levy 
JA. 1996. Suppression of HIV replication by lymphoid tissue CD8+ cells correlates 
 117 
with the clinical state of HIV-infected individuals. Proc Natl Acad Sci U S A 93: 
13125-30. 
 
108. Gomez AM, Smaill FM, Rosenthal KL. 1994. Inhibition of HIV replication by CD8+ 
T cells correlates with CD4 counts and clinical stage of disease. Clin Exp Immunol 
97: 68-75. 
 
109. Kaech SM, Wherry EJ, Ahmed R. 2002. Effector and memory T-cell differentiation: 
implications for vaccine development. Nat Rev Immunol 2: 251-62. 
 
110. Palache AM. 1997. Influenza vaccines. A reappraisal of their use. Drugs 54: 841-56. 
 
111. Hoffmann TK, Donnenberg VS, Friebe-Hoffmann U, Meyer EM, Rinaldo CR, Jr., 
DeLeo AB, Whiteside TL, Donnenberg AD. 2000. Competition of peptide-MHC 
class I tetrameric complexes with anti-CD3 provides evidence for specificity of 
peptide binding to the TCR complex. Cytometry 41: 321-8. 
 
112. Roederer M. 2001. Spectral compensation for flow cytometry: visualization 
artifacts, limitations, and caveats. Cytometry 45: 194-205. 
 
113. Baars PA, Ribeiro Do Couto LM, Leusen JH, Hooibrink B, Kuijpers TW, Lens SM, 
van Lier RA. 2000. Cytolytic mechanisms and expression of activation-regulating 
receptors on effector-type CD8+CD45RA+CD27- human T cells. J Immunol 165: 
1910-7. 
 
114. Veiga-Fernandes H, Walter U, Bourgeois C, McLean A, Rocha B. 2000. Response of 
naive and memory CD8+ T cells to antigen stimulation in vivo. Nat Immunol 1: 47-
53. 
 
115. Speiser DE, Lienard D, Pittet MJ, Batard P, Rimoldi D, Guillaume P, Cerottini JC, 
Romero P. 2002. In vivo activation of melanoma-specific CD8(+) T cells by 
endogenous tumor antigen and peptide vaccines. A comparison to virus-specific T 
cells. Eur J Immunol 32: 731-41. 
 
116. Lopez-Botet M, Bellon T, Llano M, Navarro F, Garcia P, de Miguel M. 2000. Paired 
inhibitory and triggering NK cell receptors for HLA class I molecules. Hum 
Immunol 61: 7-17. 
 
117. Ho HN, Hultin LE, Mitsuyasu RT, Matud JL, Hausner MA, Bockstoce D, Chou CC, 
O'Rourke S, Taylor JM, Giorgi JV. 1993. Circulating HIV-specific CD8+ cytotoxic 
T cells express CD38 and HLA-DR antigens. J Immunol 150: 3070-9. 
 
118. Rabin RL, Park MK, Liao F, Swofford R, Stephany D, Farber JM. 1999. 
Chemokine receptor responses on T cells are achieved through regulation of both 
receptor expression and signaling. J Immunol 162: 3840-50. 
 
 118 
119. Faint JM, Annels NE, Curnow SJ, Shields P, Pilling D, Hislop AD, Wu L, Akbar 
AN, Buckley CD, Moss PA, Adams DH, Rickinson AB, Salmon M. 2001. Memory T 
cells constitute a subset of the human CD8+CD45RA+ pool with distinct phenotypic 
and migratory characteristics. J Immunol 167: 212-20. 
 
120. Fukada K, Sobao Y, Tomiyama H, Oka S, Takiguchi M. 2002. Functional 
expression of the chemokine receptor CCR5 on virus epitope-specific memory and 
effector CD8+ T cells. J Immunol 168: 2225-32. 
 
121. Liao F, Rabin RL, Smith CS, Sharma G, Nutman TB, Farber JM. 1999. CC-
chemokine receptor 6 is expressed on diverse memory subsets of T cells and 
determines responsiveness to macrophage inflammatory protein 3 alpha. J Immunol 
162: 186-94. 
 
122. Chen G, Shankar P, Lange C, Valdez H, Skolnik PR, Wu L, Manjunath N, 
Lieberman J. 2001. CD8 T cells specific for human immunodeficiency virus, 
Epstein-Barr virus, and cytomegalovirus lack molecules for homing to lymphoid 
sites of infection. Blood 98: 156-64. 
 
123. Champagne P, Ogg GS, King AS, Knabenhans C, Ellefsen K, Nobile M, Appay V, 
Rizzardi GP, Fleury S, Lipp M, Forster R, Rowland-Jones S, Sekaly RP, McMichael 
AJ, Pantaleo G. 2001. Skewed maturation of memory HIV-specific CD8 T 
lymphocytes. Nature 410: 106-11. 
 
124. Hislop AD, Gudgeon NH, Callan MF, Fazou C, Hasegawa H, Salmon M, Rickinson 
AB. 2001. EBV-specific CD8+ T cell memory: relationships between epitope 
specificity, cell phenotype, and immediate effector function. J Immunol 167: 2019-
29. 
 
125. Tussey L, Speller S, Gallimore A, Vessey R. 2000. Functionally distinct CD8+ 
memory T cell subsets in persistent EBV infection are differentiated by migratory 
receptor expression. Eur J Immunol 30: 1823-9. 
 
126. Stoddart JH, Jr., Jasuja RR, Sikorski MA, von Andrian UH, Mier JW. 1996. 
Protease-resistant L-selectin mutants. Down-modulation by cross-linking but not 
cellular activation. J Immunol 157: 5653-9. 
 
127. Savage ND, Harris SH, Rossi AG, De Silva B, Howie SE, Layton GT, Lamb JR. 
2002. Inhibition of TCR-mediated shedding of L-selectin (CD62L) on human and 
mouse CD4+ T cells by metalloproteinase inhibition: analysis of the regulation of 
Th1/Th2 function. Eur J Immunol 32: 2905-14. 
 
128. Migaki GI, Kahn J, Kishimoto TK. 1995. Mutational analysis of the membrane-
proximal cleavage site of L-selectin: relaxed sequence specificity surrounding the 
cleavage site. J Exp Med 182: 549-57. 
 
 119 
129. Kahn J, Ingraham RH, Shirley F, Migaki GI, Kishimoto TK. 1994. Membrane 
proximal cleavage of L-selectin: identification of the cleavage site and a 6-kD 
transmembrane peptide fragment of L-selectin. J Cell Biol 125: 461-70. 
 
130. Schwaiger S, Wolf AM, Robatscher P, Jenewein B, Grubeck-Loebenstein B. 2003. 
IL-4-producing CD8+ T cells with a CD62L++(bright) phenotype accumulate in a 
subgroup of older adults and are associated with the maintenance of intact humoral 
immunity in old age. J Immunol 170: 613-9. 
 
131. Mallard E, Vernel-Pauillac F, Velu T, Lehmann F, Abastado JP, Salcedo M, 
Bercovici N. 2004. IL-2 Production by Virus- and Tumor-Specific Human CD8 T 
Cells Is Determined by Their Fine Specificity. J Immunol 172: 3963-70. 
 
132. Mailliard RB, Egawa S, Cai Q, Kalinska A, Bykovskaya SN, Lotze MT, Kapsenberg 
ML, Storkus WJ, Kalinski P. 2002. Complementary dendritic cell-activating 
function of CD8+ and CD4+ T cells: helper role of CD8+ T cells in the development 
of T helper type 1 responses. J Exp Med 195: 473-83. 
 
133. Hoji A, Rinaldo CR, Jr. 2005. Human CD8+ T cells specific for influenza A virus M1 
displays broad expression of manturation-associated phenotypic markers and 
chemokine receptors. Immunology in press. 
 
134. Tesselaar K, Arens R, van Schijndel GM, Baars PA, van der Valk MA, Borst J, van 
Oers MH, van Lier RA. 2003. Lethal T cell immunodeficiency induced by chronic 
costimulation via CD27-CD70 interactions. Nat Immunol 4: 49-54. 
 
135. Hendriks J, Xiao Y, Borst J. 2003. CD27 promotes survival of activated T cells and 
complements CD28 in generation and establishment of the effector T cell pool. J Exp 
Med 198: 1369-80. 
 
136. Ochsenbein AF, Riddell SR, Brown M, Corey L, Baerlocher GM, Lansdorp PM, 
Greenberg PD. 2004. CD27 expression promotes long-term survival of functional 
effector-memory CD8+ cytotoxic T lymphocytes in HIV-infected patients. J Exp 
Med 200: 1407-17. 
 
137. Gandhi RT, Walker BD. 2002. Immunologic control of HIV-1. Annu Rev Med 53: 
149-72. 
 
138. Day CL, Shea AK, Altfeld MA, Olson DP, Buchbinder SP, Hecht FM, Rosenberg 
ES, Walker BD, Kalams SA. 2001. Relative dominance of epitope-specific cytotoxic 
T-lymphocyte responses in human immunodeficiency virus type 1-infected persons 
with shared HLA alleles. J Virol 75: 6279-91. 
 
139. Sallusto F, Langenkamp A, Geginat J, Lanzavecchia A. 2000. Functional subsets of 
memory T cells identified by CCR7 expression. Curr Top Microbiol Immunol 251: 
167-71. 
 120 
140. Ding Z, Issekutz TB, Downey GP, Waddell TK. 2003. L-selectin stimulation 
enhances functional expression of surface CXCR4 in lymphocytes: implications for 
cellular activation during adhesion and migration. Blood 101: 4245-52. 
 
141. Appay V, Hansasuta P, Sutton J, Schrier RD, Wong JK, Furtado M, Havlir DV, 
Wolinsky SM, McMichael AJ, Richman DD, Rowland-Jones SL, Spina CA. 2002. 
Persistent HIV-1-specific cellular responses despite prolonged therapeutic viral 
suppression. Aids 16: 161-70. 
 
142. Mueller YM, Bojczuk PM, Halstead ES, Kim AH, Witek J, Altman JD, Katsikis PD. 
2003. IL-15 enhances survival and function of HIV-specific CD8+ T cells. Blood 101: 
1024-9. 
 
 
